

Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

Title	The past, present and future in scaffold-based tendon treatments
Author(s)	Lomas, A.J.; Ryan, C.N.M.; Sorushanova, A.; Shologu, N.; Sideri, A.I.; Tsioli, V.; Fthenakis, G.C.; Tzora, A.; Skoufos, I.; Quinlan, Leo R.; O Laighin, Gearóid; Mullen, A.M.; Kelly, A.M.; Kearns, J.L.; Biggs, S.; Pandit, Abhay; Zeugolis, Dimitrios I.
Publication Date	2015-04
Publication Information	Lomas, A. J., Ryan, C. N. M., Sorushanova, A., Shologu, N., Sideri, A. I., Tsioli, V. Fthenakis, G. C., Tzora, A., Skoufos, I., Quinlan, L. R., O'Laighin, G., Mullen, A. M., Kelly, J. L., Kearns, S., Biggs, M., Pandit, A., Zeugolis, D. I. (2015). The past, present and future in scaffold-based tendon treatments. Advanced Drug Delivery Reviews, 84, 257-277. doi: https://doi.org/10.1016/j.addr.2014.11.022
Publisher	Elsevier
Link to publisher's version	https://doi.org/10.1016/j.addr.2014.11.022
Item record	http://hdl.handle.net/10379/7113
DOI	http://dx.doi.org/10.1016/j.addr.2014.11.022

Downloaded 2024-05-08T14:33:39Z

Some rights reserved. For more information, please see the item record link above.



## Title:

The past, present and future in scaffold-based tendon treatments

## Authors:

A.J. Lomas<sup>1</sup>, C.N.M. Ryan<sup>1</sup>, A. Sorushanova<sup>1</sup>, N. Shologu<sup>1</sup>, A.I. Sideri<sup>2</sup>, V. Tsioli<sup>2</sup>, G.C. Fthenakis<sup>2</sup>, A. Tzora<sup>3</sup>, I. Skoufos<sup>3</sup>, L. Quinlan, G. O'Laighin, A.M. Mullen, J.L. Kelly<sup>1,4</sup>, S. Kearns<sup>1,5</sup>, M. Biggs<sup>1</sup>, A. Pandit<sup>1</sup>, D.I. Zeugolis<sup>1,\*</sup>

## Affiliations:

1. Network of Excellence for Functional Biomaterials (NFB), Biosciences Research Building, National University of Ireland Galway (NUI Galway), Galway, Ireland

2. Veterinary Faculty, University of Thessaly, Karditsa, Greece

- 3. Animal Production Division, Department of Agriculture Technology, TEI of Epirus, Arta, Greece
- 4. Department of Surgery, NUI Galway, Galway, Ireland

5. University College Hospitals Galway (UCHG), Galway, Ireland

\* Corresponding Author: Dr Dimitrios I. Zeugolis, NFB, NUI Galway, Galway, Ireland

Telephone:	+353 (0) 9149 3166
Fax:	+353 (0) 9156 3991
Email:	dimitrios.zeugolis@nuigalway.ie

## Abbreviations:

ACL, anterior cruciate ligament; ADSC adipose derived stem cell; bFGF, basic fibroblast growth factor; BMSC, bone marrow stem cell; BMP, bone morphogenic protein; DNA, deoxyribonucleic acid; ECM, extracellular matrix; EGR, early growth response protein; GAG, glycosaminoglycan; GDF, growth differentiation factor; HA, hyaluronic acid; IGF, insulin-like growth factor; MMP, matrix metalloproteinase; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; NSAIDs, non-steroidal anti-inflammatory drugs; NO, nitric oxide; Oct 4, octamer-binding transcription factor 4; PDGF, platelet-derived growth factor; PCL, poly- $\varepsilon$ -caprolactone; PLGA, poly(lactic-co-glycolic acid); PRP, platelet rich plasma; PG, proteoglycan; SSARD, slow acting anti-rheumatic drugs; SSEA-4, stage-specific embryonic antigen-4; TGF- $\beta$ , transforming growth factor- $\beta$ ; TC, tenocyte; TSC, tendon stem cells; VEGF, vascular endothelial growth factor

#### Abstract

Tendon injuries represent a significant clinical burden on healthcare systems worldwide. As the human population ages and the life expectancy increases, tendon injuries will become more prevalent, especially among young individuals with long life ahead of them. Advancements in engineering, chemistry and biology have made available an array of three-dimensional scaffold-based intervention strategies, natural or synthetic in origin. Further, functionalisation strategies, based on biophysical, biochemical and biological cues, offer control over cellular functions; localisation and sustained release of therapeutics / biologics; and the ability to positively interact with the host to promote repair and regeneration. Herein, we critically discuss current therapies and emerging technologies that aim to transform tendon treatments in the years to come.

## Keywords

Human and equine tendon injury; Tendon cellular and extracellular composition; Tendon healing; Tissue grafts; Biomaterials; Sustained and localised delivery of therapeutics / biologics

## Contents

Abstract 2
Keywords2
1. Introduction
2. Epidemiology and clinical description of human tendon injuries
3. Epidemiology and clinical description of equine tendon injuries
4. The cellular and extracellular composition of tendon tissue9
4.1 The cellular composition of tendon tissues9
4.2. The extracellular composition of tendon tissues10
5. Tendon healing
6. Minimally invasive strategies for small tendon injuries
6.1 Delivery of pharmaceutical agents14
6.2 Delivery of biological molecules – Growth factors15
6.3 Delivery of biological molecules – Genes17
6.4 Delivery of viable cell populations18
7. Surgical approaches for large tendon injuries19
7.1 Mechanical properties of tendon tissue19
7.2 Tissue grafts – The top-down approach for tendon repair
7.2 Tissue grafts – The top-down approach for tendon repair
<ul> <li>7.2 Tissue grafts – The top-down approach for tendon repair</li></ul>
<ul> <li>7.2 Tissue grafts – The top-down approach for tendon repair</li></ul>
7.2 Tissue grafts – The top-down approach for tendon repair
7.2 Tissue grafts – The top-down approach for tendon repair       20         7.3 Sutures and screws.       22         7.4 Bottom-up approached for tendon repair based on natural in origin scaffolds       23         7.5 Bottom-up approached for tendon repair based on synthetic in origin scaffolds       25         7.6 Tissue engineering by self-assembly therapies       27         8. Conclusions       28
7.2 Tissue grafts – The top-down approach for tendon repair       20         7.3 Sutures and screws       22         7.4 Bottom-up approached for tendon repair based on natural in origin scaffolds       23         7.5 Bottom-up approached for tendon repair based on synthetic in origin scaffolds       25         7.6 Tissue engineering by self-assembly therapies       27         8. Conclusions       28         9. Acknowledgements       29
7.2 Tissue grafts – The top-down approach for tendon repair       20         7.3 Sutures and screws.       22         7.4 Bottom-up approached for tendon repair based on natural in origin scaffolds       23         7.5 Bottom-up approached for tendon repair based on synthetic in origin scaffolds       25         7.6 Tissue engineering by self-assembly therapies       27         8. Conclusions.       28         9. Acknowledgements       29         10. Tables       30
7.2 Tissue grafts – The top-down approach for tendon repair       20         7.3 Sutures and screws       22         7.4 Bottom-up approached for tendon repair based on natural in origin scaffolds       23         7.5 Bottom-up approached for tendon repair based on synthetic in origin scaffolds       25         7.6 Tissue engineering by self-assembly therapies       27         8. Conclusions       28         9. Acknowledgements       29         10. Tables       30         11. Figures       36

## 1. Introduction

Tendon injuries constitute an unmet clinical need for both human and equine patients. Over 30 million human tendon-related procedures take place annually worldwide with an estimated healthcare expenditure in excess of  $\in$ 140 billion per year [1]. As the human population ages and life expectancy increases, it is estimated that 25% of all adults will suffer a tendon related condition that will put a further physical and financial strain on healthcare systems [2, 3]. Proportional is the situation with equine patients: 46% of the racehorses will suffer a tendon-related injury that will negatively impact the industry, which is valued at  $\in$ 400 billion worldwide [4, 5].

Subject to the severity of the injury, from a small sprain to a complete rupture, numerous therapeutic strategies of variable efficacy are currently available (**Table 1**). Unfortunately, preclinical and clinical data to-date indicate, regardless of injury severity, no current therapies have achieved complete pre-injury state recovery [6]. Further, severe injuries are often associated with compromised function, joint instability and long-term pain and disabilities, due to the inherent poor regeneration capacity of tendon [7].

These findings impose the need for the development of functional therapies for injured tendon tissues. However, for successful tissue engineered therapies, it is important to understand epidemiological data of the different injuries, the function of cellular and extracellular components in tendon physiology and healing, and pioneered technologies that have become available in recent years. Upon this knowledge, it is likely to revolutionise functional tendon treatments in the years to come.

## 2. Epidemiology and clinical description of human tendon injuries

The most frequently injured tendons are the shoulder rotator cuff, the forearm extensor, the hand flexor, the Achilles, the tibialis posterior and the patellar [8, 9], while the anterior cruciate ligament (ACL) is one of the most painful and debilitating of knee injuries [8, 9]. Previously, the tendon research community recognised inflammation as the underlying cause of tendon injury, however, with advancements in imaging technologies and understanding of histopathology, it is widely accepted that tendon injuries are more degenerative in nature [10-14]. These degenerative conditions, referred to as tendinopathies, comprise of typical pathological changes, including islands of high cellularity and initial tissue disorganisation in mild degeneration, whilst in severe degeneration is accompanied by chondrocyte appearance [15]. Macroscopically, degenerative tissue appears to be yellow / brown due to mucoid degeneration and the loss of the highly organised appearance of collagen fibre bundles [14, 16]. Further, microscopic changes occur within the collagen structure itself and fibrosis and neovascularisation are evident [17-19]. In addition, current data suggest that the formation of additional blood vessels is responsible for the pain prevalent in tendinopathies [20, 21], and not inflammatory infiltration, as previously suspected [22, 23].

16% of the general population, 21% of elderly people and 80% of individuals older than 80 years sustain rotator cuff injuries [10], with full or partial tears affecting 27% and 37% of the general population respectively, with high recurrence rate, despite surgical repair [11, 12]. Rotator cuff tears impair shoulder function, cause pain and lead to degenerative changes in the glenohumeral joint. Partial tears are customarily treated through means of physiotherapy. Surgical treatments include arthroscopic cuff decompression and repair and, in severe cases, open surgery [13, 14]. Debridement is undertaken when <50% of the rotator cuff is torn; in cases where >50% of the tendon is torn, partial or complete repair, usually with substitutes and various tendon transfers, is utilised [15, 16]. Graft augmentation is employed for long-standing tears of medium to large extent [17, 18]. Unfortunately, graft augmentation is associated with high tear recurrence (94%), subject to the size of the initial tear, the degree of muscular atrophy, the fatty infiltration, the tendon quality and the post-surgical rehabilitation protocol [19-21].

Hand flexor tendon injuries are more frequently encountered in younger patients [22]. Clinical presentation is characterised by pain, tenderness, swelling and erythema of the affected tendons [23]. Surgery treatment strategies for the tendon and the sheath are based on suturing, followed by active motion post-surgery [24]. However, reoperation following flexor tendon repair is necessary in as high as 17% of cases [24-26], with unsatisfactory outcomes reported by up to 20% of patients [27]. It has also been reported that reoperation is required more often in older patients [28]. Rupture of the Achilles tendon is a common sport-related injury, with degeneration occurring in an estimated 11% of runners [29], with the highest incidence of rupture seen in 30- to 50- years old

males [25]. Clinical diagnosis is based on palpation of the gap and a positive Thompson test, with ultrasonography and/or magnetic resonance imaging (MRI) used to confirm the diagnosis [25, 26]. Surgical treatment is necessary in one-third of the patients [27] and includes minimally invasive, percutaneous or open repair strategies, subject to the extent of the injury. Unfortunately, future complications and treatment failures are common [28-30]. Injury of the tibialis posterior tendon occurs more commonly in middle-aged women, with clinical features including pain in the medial foot, loss of function and flatfoot deformity with no history of pre-existing trauma [31]. Therapeutic approaches include surgical tendon reconstruction (debridement of the tendon or tendon transfer), calcaneal osteotomy and arthrodesis [32]. Patellar tendon injury usually occurs in active adults younger than 40 years and jumping sport athletes. Clinical diagnosis is based on presence of pain, difficulty to stand and palpation of a subcutaneous depression at the region. X-ray, ultrasonography and/or MRI methods are used to confirm the diagnosis and are particularly useful in patients with long-standing, mild clinical signs [33]. Primary repair is the treatment of choice in recent years, whilst chronic injuries necessitate graft augmentation. ACL injury occurs predominantly in the male population due to increased exposure to physical tasks and involvement in sports; however females have been identified to be at higher risk of injury [30]. Patients experience joint instability and knee pain following non-surgical treatments [31-33] and risk further injury within the knee, when the ACL is working at insufficient functional capacity [34]. Reconstructive surgery is usually performed instead of partial repairs, due to the poor healing capability of the ligament [35]. The most successful reconstructions implement biological tissue grafts, due to joint integration and optimal remodelling [36]. However, preclinical studies have shown that the biomechanical properties, including load to failure and stiffness, of new ligaments are mechanically deficient compared to normal by up to a quarter within a year following surgery [37-39].

## 3. Epidemiology and clinical description of equine tendon injuries

In sporting horses, energy-storing tendons often stretch close to failure strain limit, especially during jumping at high-speed locomotion, which explains why tendons, such as the superficial digital flexor, are more prone to strain injuries [40]. In contrast, tendons not subjected to such increased forces, such as the deep digital flexor, show a significantly smaller incidence of strain injuries [41]. Intrinsic (e.g. age, bodyweight, organ fatigue) and external (e.g. track surfaces) reasons have been described as predisposing factors [42]. Regardless of the cause, all equine tendon injuries heal slowly and improperly due to the formation of permanent disordered scar tissue [43]. Upon healing, the repaired tendon increases in size and becomes structurally strong with increased stiffness [44]. Restrictive adhesions develop within the synovial sheath of the tendon, leading to impaired functionality in daily activity and, ultimately, to reduced performance of the animal and increased risk for re-rupture [45].

The majority of equine mild strain injuries occur to the forelimb tendons, with the superficial digital flexor tendon being involved in up to 90% of incidents [46]. Such injuries usually occur at the midmetacarpal region, in the central part of the tendon. Mild injuries of the superficial digital flexor tendon are clinically manifested initially with severe lameness, which although may resolve rapidly, it will remain as an on-going problem. Careful palpation of the affected limb at the metacarpal area would elicit a pain response from the animal and reveal an oedematous region. Ultrasonography imaging is essential for confirmation of the clinical diagnosis, as well as for the identification of the exact location and the severity of the injury. Upon diagnosis, treatment should start immediately to avoid further damage [47]. Therapeutic options include a conservative approach (general rest, support bandaging and reduced activity over an extended period of time), as well as surgical proximal check desmotomy and/or tendon splitting. Transection of the proximal check ligament increases the elastic limit of the tendon by allowing the muscle to contribute to the overall elasticity; however this may be compromised by the formation of the scar tissue [48, 49]. Tendon splitting should be performed soon after the injury occurs, in order to minimise damage by proteolytic enzymes released [50]. Injuries of the deep digital flexor tendon are rare, affecting mainly the tendon within the digital sheath. Should it occur, brought about lameness is severe and persists for a long period of time, with oedematous appearance of the region and pain reaction present during clinical examination. Ultrasonography and MRI are used for confirmation of diagnosis [51]. Bursoscopy may also be used diagnostically, with the added advantage of facilitating surgical management of the lesions. Conservative treatment, such as box rest, can also be applied, but in general, prognosis for return to exercise is guarded [52].

Although tendon lacerations are usually the result of cuts by sharp objects, they can also occur during sporting events [47]. Careful examination of the limb conformation during weight bearing

and ambulation provides useful information regarding tendons involved. When the superficial digital flexor tendon is lacerated, a significant hyperextension of the metatarsophalangeal joint is evidenced. When the deep digital flexor tendon is compromised, the distal interphalangeal joint is hyperextended, resulting in the toe being elevated from the ground. Concurrent laceration of the above two tendons and the suspensory ligament result in the pastern resting on the ground and the toe being elevated [53]. Management of lacerations in non-sheathed zones of the tendon(s) aims to reduce gap and adhesion formation and preserve the intrinsic healing process. Tenorrhaphy is usually performed, preferably by the three-loop pulley technique [54]. When lacerations at the sheathed zone of the tendon have occurred, adhesions and septic tenosynovitis are common complications; tenorrhaphy within the sheathed zones is not recommended, as it cannot prevent gap creation between tendon ends or formation of adhesions [55, 56]. Lacerations of the digital extensor tendons are common, both in the fore- and hind- limbs. In such cases, lameness is minimal and treatment requires debridement of the wound. For these injuries, suturing of the tendon is usually not required [50]. Laceration of the long and lateral digital extensor tendons may not elicit any gait abnormalities, whereas transection may lead to abnormalities in protraction of the limb and knuckling of the toe. Tendon end suturing is performed only in recent, clean and sharp lacerations in the non-sheathed zones of the tendons; in all other cases, second intention healing (debridement, lavage, drainage) is preferred [57].

#### 4. The cellular and extracellular composition of tendon tissue

#### 4.1 The cellular composition of tendon tissues

Human and equine tendons are comprised of various cell populations (**Figure 1** and **Table 2**), with similar characteristics between species [58, 59]. Around 90-95% of the cells present in tendon are elongated specialised fibroblasts, termed tenocytes (TC), and their precursor cells, termed tenoblasts. In embryonic and juvenile tendons, TCs are numerous and found within close proximity to the developing collagen fibres. In mature tendons, TCs reduce in number and flatten, with cytoplasmic processes shortening and diminishing in number [60]. They form a network of cellular protrusions, allowing them to react cohesively to external forces and enabling the tissue to react best to mechanical demands [61]. Tenoblasts vary in size and shape ranging from round, spherical or cuboid to spindle star like morphologies of between 20 and  $70\mu$ m in length and 8 to  $20\mu$ m in width and have been considered to be the major cell type responsible for tissue remodelling [62]. Upon maturation into TCs, they become elongated with up to  $300\mu$ m length and less metabolically active [63], suggesting that they play different role in tendon physiology than tenoblasts. Commonly used markers include collagen type I, collagen type III, decorin, scleraxis, tenascin C, tenomodulin and thrombospondin 4. However, specific markers to distinguish tenoblasts from TCs are yet to be identified.

The remaining 10% of cells present in tendon are a combination of progenitor cells (tendon stem cells; TSCs), chondrocytes (found towards the bone junction), vascular endothelial cells (found in surrounding vascular network), synovial cells (found in the tendon sheath) and smooth muscle cells (found toward the musculotendon junction) [58, 64]. TSCs are a recently discovered population of cells resident in tendon that have the capacity to differentiate into bone, cartilage and fat [65]. In addition to this multi-lineage potential, rabbit TSCs have been found to express the stem cells markers octamer-binding transcription factor 4 (Oct 4) and stage-specific embryonic antigen-4 (SSEA-4) and to have significantly longer population doubling times to TCs isolated from the same tendon source [66]. The concentration of TSCs has been found to vary with age, position and species, with tendons from younger specimens containing higher numbers [67]. Perivascular cells are found in the walls of internal and external tendon capillaries and have been identified as cells that could have a regenerative capacity. They are expressing both mature tendon and stem cell related markers, after being isolated and cultured in vitro [68, 69]. Further small populations of mesenchymal stem cells (MSC) have also been identified to be present in both equine and human tendons, although they are generally not recognised as a site for potential stem cell source, due to their poor availability [70]. Fat pads not only aid tendon mechanical function [71], but also provide a source of adipose derived stem cells (ADSCs), with regenerative potential [72].

#### 4.2. The extracellular composition of tendon tissues

Collagens, elastin, glycosaminoglycans (GAGs) and proteoglycans (PGs) make up the load bearing structures of human and equine tendon tissues (Figure 1), with slight variations in their concentration between tendons found in different parts of the body. In tendon, collagen type I is the major constituent, making up around 80-90% of the tendon dry mass [58]. Collagen fibres perform several functions, including maintenance of tissue architecture, transmission and absorption loads and prevention against mechanical failure [73, 74]. The base unit of collagen I is a triple helical hetero-polymer consisting of two  $\alpha 1(I)$  chains and one  $\alpha 2(I)$  chain [75]. To form this structure, each left handed helical  $\alpha$ -chain is staggered by one residue relative to each other to coil about a central axis, forming a right-handed super-helix [76, 77]. The helix is stabilised by hydrogen bonds between adjacent glycine domains and between the hydroxyl groups of hydroxyproline residues. If the positioning of these molecules is incorrect, or the molecules are not present, the collagen will degrade rapidly [78]. Collagen triple helices spontaneously self-assemble in the extracellular space, following or during secretion, to form quarter staggered fibrils with a characteristic 67nm periodicity (D banding) created by the alternating overlap and gap regions [79-81]. Subsequent cross-linking takes place that provides collagen fibrils with high degree of axial alignment and enhances tissue integrity and mechanical resilience. It has been proposed that intermolecular crosslinking occurs in two ways; firstly longitudinal cross-linking of the end-overlapped molecules, and secondly by the interaction of these cross-links between two molecules in parallel [82].

Other, less abundant collagen molecules (e.g. collagen types III, V, XII, XIV) are particularly important when examining tendon aging and pathophysiologies [83, 84]. In healthy tendon, type III collagen is found predominantly in the endotenon and epitenon layers surrounding the collagen type I fibrils [85]. Aging and tissue damage reduces its content, resulting in reduction in tendon elasticity [86, 87]. Type V collagen is found at the centre of the collagen fibrils and mediates fibril development and diameter growth. This process ensures that a collection of many small collagen I fibres are formed, rather than one large structure [88, 89]. Collagens XII and XIV are also present in tendons in small quantities [90, 91]. These collagens act as supplementary molecules in the force transition process, aiding collagen I bundles to glide over each other when a force is applied by decreasing interactions between fibres and thus preventing potential tendon injury [92].

Elastin is present in tendon in the form of elastic fibres and makes up between 1 and 2% of the total dry mass [58]. Elastin molecules are composed of alternating hydrophobic and lysine-rich cross-linking domains, which are critical for molecular structural assembly and elastic function [93]. During structural assembly, the lysine side chains oxidise, via the enzyme lysyl oxidase, allowing the formation of covalent cross-links with neighbouring molecules [94, 95]. The elastic properties are created by the hydrophobic regions, which adopt a random coil configuration following

extension [96]. Overextension is prevented by covalent cross-links that provide tendon tissues with a high degree of flexibility, ensuring complete recovery of the wavy configuration of the surrounding attached collagen fibres, after muscle contraction and tendon stretch [97].

GAGs and PGs, although encountered in miniscule amounts in tissues, are involved in many physiological processes, including collagen fibril formation, growth factor interaction, cell-cell interactions and cell regulation [98, 99]. In addition, GAGs and PGs are highly polar molecules that attract water and therefore play key role as lubricants and shock absorbers. This water absorption capacity allows fibrils to slip over each other during mechanical deformation, preventing breakage. Further, GAGs and PGs provide several cell adhesion sites [100]. The PG composition of tendons depends on both its location and role in the body. Compression bearing tendons, such as the supraspinatus tendon found in the shoulder, have a significantly higher PG content than tension tendons, such as the biceps (3.5% versus 0.2% of total tendon dry weight) [101]. In highly active tendons, such as the equine super digital flexor tendon, PG content within the tendon can be much higher than in non-stressed tendons, with several studies concluding that PG content is directly related to the load bearing capacity of the tendon [102]. The most common encountered PGs in tendon are decorin, versican and aggrecan and can be grouped based on the nature of their GAG chains. Specifically, decorin is commonly associated with dermatan sulphate [103], aggrecan with a combination of dermatan sulphate and keratan sulphate [104] and versican with chondroitin sulphate [103]. In tendon, dermatan sulphate is thought to provide a mechanism of the limitation growth of collagen fibrils, preventing the diameter of individual fibrils becoming too large and maintaining the hierarchical structure seen in connective tissues, thus helping to maintain their physical properties, while chondroitin sulphate plays a vital role in maintaining the amount of water retained by the tissue and controlling the organisation of the collagen present, specifically void space and overall tissue stiffness [105]. The location of the tendon and the specific area of the tendon denominates which PG is most prevalent. Decorin, for example, is the major PG in the central load bearing tendon regions, whilst versican is identified in areas of bone insertion and where compressive forces are prevalent [106].

#### 5. Tendon healing

The wound healing process in tendons occurs in three overlapping phases (**Figure 2**), which are regulated by various growth factors, cytokines and cell types. In the first (inflammation) phase, inflammatory cells migrate into the injury site and phagocytise necrotic tissue and clot. In the second (repair) phase, fibroblasts proliferate in the injury site and synthesise and deposit extracellular matrix (ECM) components. In the third and final (remodelling) phase, the newly produced collagen fibres are aligned along the longitudinal axis of the tendon and eventually become capable of sustaining loads [107]. Over the years, two healing mechanisms have been proposed, subject to the cell populations participating. Intrinsic healing is predominantly controlled by resident TCs, whilst the extrinsic is controlled by cells migrating from the external surrounding tissues [108]. Due to the low activity / reparative capacity of the resident cells [1, 109-112], the extrinsic healing mechanism is activated. In reality, it is likely that a combination of both mechanisms occurs, with different injuries and injury sites determining which mechanism is the overriding one [113].

A by-product of the extrinsic healing process is that extensive amounts of disorganised collagen are deposited, resulting in scar tissue formation and adhesions between the neotissue formed and surrounding tissues. Scar tissue has reduced overall mechanical properties and is associated with an increased chance of re-rupture in later life [114]. Further, increased concentration of collagen type III, remained at the wound site during healing, could also lead to reduced mechanical properties [115]. The presence and arrangement of non-collagenous macromolecules is also altered during tendon healing, even after long periods of recovery [116] and has been found to be dependent on the healing stage. Biglycan expression, for example, is upregulated in the early phases of tendon regeneration, whilst decorin expression is increased during the remodelling phase [117]. The influx of extrinsic cells into a wound area results in increased number of cell populations (e.g. vascular endothelial cells, fibroblasts and stem cells) not usually seen in healthy tendons [107]. These cells could dominate endogenous TCs, especially with respect to cellular secretome, resulting in compromised functionality [118] and adhesion formation that are associated with pain and locomotion issues [119]. As a result of these changes, mechanical, structural, biochemical and biological properties of the healed tendon never match those of the tissue prior to injury [64]. Thus, it has been proposed that tendon therapies, based on injectable systems or implantable devices, should enhance the intrinsic and suppress the extrinsic healing mode, in order to better restore tendon function [120].

#### 6. Minimally invasive strategies for small tendon injuries

Injectable systems allow localisation of the cargo and its sustained release at the side of injury, increasing that way the effectiveness of the treatment. Among the natural biopolymers, collagen type I and fibrin are the most widely used [121, 122], although the use of hyaluronic acid (HA) has also been advocated as it allows tissue integration and prevents adhesions to surrounding tissues [123]. The attractiveness of collagen type I is based on the fact that constitutes the major component of tendon and is removed from the body through physiological enzymatic processes, as a function of the extent of cross-linking and functionalisation [105, 124-127]. Clinically, injectable collagen hydrogels have been utilised as carriers for biological and pharmaceutical agents [128]. Collagen peptides have also been used, with preclinical data demonstrating increased collagen synthesis [129], maintenance of homeostasis [130] and improved healing, as judged by mean average diameter, distribution of fibrils and GAG composition [131]. The utilisation of fibrin has been advocated based on its high cytocompatibility, biodegradability, controllable cross-linking, carrier capacity and presence of several ECM proteins, such as fibronectin, that enhance cell adhesion and proliferation [132-134]. Preclinical analysis revealed that fibrin glue around the suture site enabled rabbit flexor tendon healing with smooth gliding surface and without formation of adhesions [119]. In a rat supraspinatus tendon defect model, although fibrin clot improved collagen organisation and mechanical properties over time and reduced cellularity, the biomechanical properties did not reach the properties of the healthy tissue by week 12 post-implantation [135]. In a ruptured Achilles tendon model, biomechanical and histological analysis revealed comparable characteristics between fibrin- and suture-based repairs [136, 137]. Clinical data also advocate the use of fibrin; in an Achilles tendon repair situation, although complete restoration of healthy tendon properties was not achieved, functional and cosmetic results were significantly improved [138, 139]. To-date, injectable systems, loaded with pharmaceutical agents, biological molecules and viable cell populations are under intense research and development in the quest of recapitulating native tendon function following injury.

#### 6.1 Delivery of pharmaceutical agents

Anti-inflammatory molecules, such as slow acting anti-rheumatic drugs (SAARDs) or non-steroidal anti-inflammatory drugs (NSAIDs), are extensively used in tendinopathy [140]. Data to-date demonstrate reduction in inflammation observed during the early stages of tendinopathy and maintenance of tendon structural integrity and mechanical properties [141]. However, the effective window of SAARDs is limited to the very early stages (at most 2 years after degeneration has begun) of tendon damage [142]. Similarly, NSAIDs have a beneficial effect on injured tendons, should they injected soon after the injury occurs (a few days); however, patient response to the treatment varies widely, side effects associated with prolonged use and their detrimental effect on cell proliferation and PG synthesis further compromise their use [143-145]. The use of glucocorticoids, as inflammation suppressive drugs, has also been advocated in tendon field [59], however *in vitro* studies demonstrate suppression in PG production, which may hinder regenerative processes [146].

Given nitric oxide (NO) is normally expressed in healthy tendon, albeit at low levels, and is diminished in fibrous tendon scar tissue, its use following tendon injury and in tendinopathy has been advocated [147, 148]. Topical gels and slow release patches have been used as delivery vehicles [147, 149]. Clinical findings using topical gels show improved early stage healing and pain reduction, and long term improvements in functionality [150], however, natural tolerance can occur in long term treatments leading to reduced therapeutic benefit and side effects, such as headaches, have been reported in some cases, limiting the use of NO to specific tendon conditions [151].

HA has been utilised in tendon therapy for several years in both equine [152] and human patients [153]. Long term follow up studies on athletes with patellar tendon injuries demonstrated that HA injections directly into the tendon and surrounding areas have a beneficial effect on tendon healing, as assessed by scoring methods [154]. Further studies investigating repeated HA injections to hand damaged flexor tendons indicated reduction in adhesions with surrounding tissues [155]. Similar small animal model studies have identified reduction in adhesion formation as the primary mode of action of HA in tendon healing [156].

Intra-tissue injections are the preferred delivery mode of pharmaceuticals for both human and equine patients. The cost-benefit of pharmaceuticals to treat tendon injuries, especially the use of corticosteroid, is under severe scrutiny with respect to their efficacy and associated side effects [157-160]. Given there is currently no sufficiently effective pharmaceutical-based therapy, the use of more potent biological molecules was proposed as an alternative strategy.

#### 6.2 Delivery of biological molecules – Growth factors

Growth factors, natural functional molecules that stimulate cellular processes [161], have been extensively studied as means to recapitulate native tendon function following injury [162-164], given their role in tendon physiology and healing, through cell recruitment at the site of injury and stimulation of ECM synthesis [165-168]. For example, vascular endothelial growth factor (VEGF) increases revascularisation of repairing tendon tissue, improving overall healing [169]; plateletderived growth factor (PDGF) has beneficial effects on the functional repair of tendon tissue in the canine model, increasing tendon glide, but not mechanical properties, over a 42 day period [170]; basic fibroblast growth factor (bFGF) stimulates both MSC proliferation and differentiation towards tenogenic lineage, leading to increased expression of tendon specific ECM proteins and increased collagen production from cells [171]; bone morphogenic protein 12 (BMP-12), also referred to as growth differentiation factor 7 (GDF-7) induces both in vitro and in vivo tenogenesis of MSCs in both human and equine cells [172-174]; BMP-13 (GDF-6) induces an increase in the expression of tendon specific proteins in rat MSCs along with increasing the characteristic wave like pattern found in tendon histological samples after 14 days implantation in a rat Achilles defect model [175]; BMP-14 (GDF-5) reduces adhesion formation between tendons and surrounding tissues, improving overall function and recovery [176]; early growth response protein 1 (EGR1) directs tendon differentiation in rat MSCs and improve tendon healing in a rat Achilles tendon injury model [177]; and transforming growth factor- $\beta$  (TGF- $\beta$ ) is highly influential in the recruitment and maintenance of TC progenitor cells during injury [178]. While these growth factors have demonstrated efficacy, as assessed by increased cellular migration, matrix production and matrix mechanical properties over a short period of time (up to around 8 weeks), little difference has been documented in long term tissue integration, matrix composition and overall tissue strength over control groups [177, 178]. To this end, the use of single growth factor injections [179] or cocktails of thereof [180] at different healing stages has been proposed [181]. However, single or combinatory growth factor injectable therapies have not reached clinical use.

Despite the promising preliminary results achieved, the literally infinite number of growth factor combinations, dose regimes and injection time, makes the identification of a suitable therapy elusive. To this end, platelet rich plasma (PRP), a natural concentrate of many growth factors [182-184], is under intense investigation. PRP has been proposed as a therapy for the treatment of equine tendon injuries, with data demonstrating development and maturation of a healing tendon tissue, based on improved metabolic activity, increased failure strength and elastic modulus of the repairing tissues and increased neovascularisation, over the saline injected counterparts in an equine superficial digital flexor tendon model [185-188]. In a clinical setting, PRP injections have been used under various identifying names for decades [189, 190]; however long-term, large and blinded

studies have yet to be reported, with current data contradicting each other. Pilot studies, for example, have demonstrated safety of either PRP alone or in conjunction with other therapies including surgical suturing techniques and physiotherapy [191-194]. On the other hand, the use of PRP injections is opposed based on data demonstrating no added value in patients received anterior cruciate ligament (ACL) allograft replacement and PRP injections [195] and on data revealing tendon thickening, pain and reduction in mechanical properties, following PRP injections [196-198]. Primary limitations of this approach include the lack of standardisation for PRP potency, preparation and dosing. It is well recognised that PRP preparations used clinically depend upon their human source and preparation methods and that age, health indices and genetics comprise part of the complex matrix that determines PRP potency. Many of the inconsistencies and variables in the PRP literature result from a widely varying PRP product applied for healing purposes [182, 189, 190, 194]. For example, it is necessary for PRP to be clotted for delivery to the target site, thus traditionally bovine thrombin is implemented; however, this adds the risk of coagulopathies due to the induction of the production of antibodies to clotting factors [199]. To this end, other clotting agents, such as fibrin and collagen I, have been studied [200, 201], which make comparison between studies even more complicated. It has been suggested that PRP products should be derived from the patient's blood, given that platelet concentrations vary between individuals and even between samples taken from the same patient under different conditions [202], making commercialisation of such technology even more complicated.

#### 6.3 Delivery of biological molecules – Genes

Gene delivery systems, which utilise the action of transfecting mRNA sequences into cells to genetically alter their DNA and induce expression, upregulation or downregulation of proteins, have also been proposed as injectable tendon therapy systems [203]. Preclinical studies have demonstrated the potential for gene therapy in tendon and ligament repair. Collagen hydrogels loaded with TGF- $\beta$  adenovirus have been shown to transduce invading endogenous cells in both *in* vitro and in vivo models over a 21 day period, with transduced cells found up to 6mm from the hydrogel / tissue junction, demonstrating its potential for use in the clinic [204]. TGF- $\beta$  has been used to transduce rat muscle cells for use in the repair of induced tendon injuries, with gene-treated cell grafts leading to almost normal histological appearance, greater mechanical strength and higher presence of collagen I over an 8 week study period, again demonstrating its potential effectiveness for clinical use [205]. Fibromodulin plasmid with micro-bubbles were injected into the Achilles tendon of wild type and fibromodulin deficient mutant mice and burst *in situ* using high intensity ultrasound. High transfection efficiency was achieved up to 19 days and gene expression was detectable for over 100 days. Further, the collagen fibril diameter in mutant mice was comparable to that of wild type mice, demonstrating the method's potential effectiveness for delivering gene therapies for degenerative tendon disease treatment [206]. However, mechanical analysis of recovered tendon was not performed to demonstrate therapeutic efficacy. Recent work investigating the use of injectable poly(lactic-co-glycolic acid) (PLGA) nanoparticles to transfect intrinsic cells in *vivo* with TGF- $\beta$  in a chicken foot induced defect model demonstrated sustained delivery for over a 4 week period, leading to a small, but significant reduction in adhesion formation. However a large significant reduction in tendon mechanical properties was recorded [207], demonstrating that while some aspects of tendon healing can be improved by using this method, further work is needed to enable overall therapeutic benefits. Although gene therapy has great potential in difficult to cure injuries and degenerative conditions (e.g. spinal cord injury, Alzheimer's disease, arthritis), gene transfer is associated with potent host inflammatory and immune responses [208, 209] and therefore its clinical potential for small, non-life threating tendon injuries (e.g. tennis elbow) is questionable [210].

#### 6.4 Delivery of viable cell populations

The limited regenerative capacity of tendons has been attributed to the low activity and low reparative potential of the resident cells [1, 109, 110, 112]. Further, permanently differentiated and stem cell populations act as a *biological factory* [1] of a spectrum of bioactive and biotrophic molecules that regulate several physiological processes [211-213]. Thus, delivery of cells is clearly more beneficial than any single or even dual biological molecule delivery strategy, which has little chance of commercialisation, given the complexity of the system. To this end, direct cell injections were pioneered, with positive results in equine patients [44, 214], even with low number of cells [215-217]. However, direct cell injections have failed to deliver in a consistent manner in humans due to poor cell localisation [218-221], triggering an extensive investigation into the optimal cell carrier for tendon repair [1]. The ideal carrier system should prevent cell membrane rupture during the injection process; create increased tissue integration through fast *in situ* self-assembly; facilitate long-term cell survival and functionality maintenance; and allow spatiotemporal release of the cargo [222-231]. Preclinical data using either collagen [232] or fibrin [233] hydrogels have demonstrated improved mechanical properties, histological scores, tissue integration and restored functionality using TCs and various stem cell populations [234, 235], however clinical use of injectable cell/hydrogel systems is still to be realised.

Biologically informed advancements in chemistry have made available stimuli responsive polymers that can controllably react to environmental stimuli, such as temperature, pH, enzymes, affinity ligands, oxidative stress, magnetic / electric fields, mechanical loading [236, 237] and release their cargo. Matrix metalloproteinase (MMP) [238-240] or mechanical stimuli [241] responsive polymers are expected to pioneer tendon therapies in the years to come due to their sensitivity / specificity to the local tissue microenvironment. For example, MMP activity is increased in tendon rupture and overuse [242-244] and therefore can be used as a trigger for the stimuli-responsive carrier to release its cargo.

#### 7. Surgical approaches for large tendon injuries

When tendon injuries are associated with large defects, implantable devices with sufficient mechanical resilience are required to bridge the gap. To this end, tissue grafts and three-dimensional natural or synthetic in origin scaffolds, that closely imitate native tendon architecture, are at the forefront of scientific and technological research and development. Before though we are in position to develop a suitable implantable device with adequate mechanical properties, it is essential to understand the mechanical properties of the native tissue.

#### 7.1 Mechanical properties of tendon tissue

The primary function of tendons is linking and transmitting forces generated by muscle to bone, in order to mobilise and stabilise the joints that they cross. Tendons exhibit viscoelastic and plastic properties, both essential in transmitting muscle-contraction-induced tensile strains into movements, whilst maintaining structural integrity [245-247]. The collagenous network is considered to be the main load-bearing structure, through intra- and inter- molecular cross-links between the adjacent helical molecules [248-252]. Non-collagenous macromolecules are also important, but to a lesser extent [253, 254]. For example, the viscoelastic properties of elastin and presence of proteoglycans allow tendons withstanding compressive and tensile forces [255, 256].

The deformation mechanism of tendons is similar to those of crystalline polymers that yield and undergo plastic flow [257-265]. The yielding mechanism involves some form of flow, such as interfibrillar slippage, which is crucial in the tensile deformation of tendons [266, 267]. During loading of collagen molecules, fibrils, and fibril bundles deform and finally fail by a process termed defibrillation. Up to a strain of 2% (toe region), stretching of the triple helix is the predominant mechanism of deformation [268-271] and corresponds to the gradual removal of a macroscopic crimp in the collagen fibrils [272-281]. This macroscopic crimp has been characterised as the shock absorber of tendons that permits non-damaging longitudinal elongation of fibrils within the tissue [261, 282]. At strains beyond 2% strain, the low modulus of the toe region gives rise to the nonlinear heel region, during which reorientation and un-crimping of the collagen fibrils and stretching of the triple helix, the non-helical ends and the cross-links takes place [269, 271, 283]. When collagen is stretched beyond the heel region, no further extension is possible [259, 270, 284, 285], the wavy pattern is now straightened and cross-links and fibrils start breaking [261]. To-date, advances in chemistry and engineering have made available numerous polymers, cross-linking systems and scaffold fabrication technologies that closely imitate the biomechanical properties of native tendons (Table 3).

#### 7.2 Tissue grafts – The top-down approach for tendon repair

The current gold standard in clinical practice for large tendon defects is autologous, allogeneic or xenogeneic in nature tissue grafts [2, 3]. The choice of the site from which an autograft will be harvested depends on tissue accessibility and availability; on the physical dimensions and mechanical properties of the donor tissue; and on the extent of site morbidity that will be induced [286, 287]. The use of autografts in clinical setting has been strongly supported by superior functional results [288, 289]. Nonetheless, availability issues and the unavoidable site morbidity that will only partially improve the properties of the originally injured tendon tissue [290-293] pushed the field towards allogeneic [294-298] alternatives. Clinical data indicated no functional difference between autograft and allograft intervention in ACL repair [299-301]; however MRI analysis favoured the autograft, as allograft intervention brought about a less mature neotissue [302]. The use of autografts in ACL reconstruction has been further reinforced with recent data indicating that allografts are almost 6.7 times more likely to fail, when compared to autografts [303]. Further, it has been suggested that mismatch in age, activity and body weight between donor and recipient may be crucial factors in the failure of allografts for ACL reconstruction [304]. In addition, the use of allografts is further limited by their higher overall surgical costs; approximately US\$ 1,000 extra per clinical case [305, 306]. For these reasons, the use of xenografts took off, with numerous products currently available [307, 308]. Although positive functional scores and improved movement as early as 6 months post-operation have been reported [309], many studies have demonstrated high failure rates and tearing incidents [310-313], which may be attributed to processing conditions (e.g. decellularisation, cross-linking, sterilisation) employed to battle immune rejection, which remains the major obstacle for both allogeneic [314, 315] and xenogeneic [316] approaches.

Significant advancements in chemistry and biology, combined with the inherent capacity of tissue grafts to closely imitate the native tissue composition and architecture, it is likely to yield a functional therapy in years to come. For example, in a canine model, HA functionalised allografts demonstrated significant reduction in adhesions, without any negative effect in cellularity and mechanical properties [317, 318], whilst HA pre-treatment in a rabbit ACL model demonstrated mechanical integrity maintenance and improved healing [319]. Separate studies investigating the effect of the addition of HA molecules to the surface of allografts in canine models found that adhesions to surrounding tissue, were reduced when HA was used 6 weeks post-surgery, and that HA had no effect on the cellularity of tissues after removal or overall tissue mechanical properties [317, 318]. This has been confirmed in the rabbit model [319]. Gene delivery has also been investigated using GDF-5 (BMP-14) loaded freeze dried allograft tissues, finding that adhesions can

be reduced and fibril alignment improved in a murine Achilles model over control tendon grafts [320], however gene functionalised grafts have not been translated to the clinic as yet.

Functionalisation of allografts with autologous cells has also reached preclinical assessment. *In vitro* studies demonstrate that tendon grafts support the growth of human ADSCs for up to 14 days in culture, resulting in increased tensile strength and collagen density [297]. Further studies demonstrated that mechanical stimulation of TC recellularised rabbit flexor tendons resulted in increased ultimate tensile strength and elastic modulus of the graft tissues after 4 weeks *in vivo* [321]. Sectioned canine decellularised tendons stacked into layers and loaded with bone marrow stem cells (BMSCs) increased expression of tendon specific markers [322]. However the mechanical properties of these structures were not influenced by the addition of cells, possibly due to the static conditions the graft composites were cultured in.

Studies assessing the recellularisation potential of BMSCs, ADSCs, TCs and sheath fibroblasts indicated that prolonged culture time (6 weeks) was required for recellularisation of tissue grafts [323]. Indeed, harsh cross-linking methods, employed to control the immunogenicity of the device, create a compact structure and are often associated with foreign body response, compromising healing. Thus, biomaterial-based approaches are under investigation, as they provide the opportunity to treat tendon injuries, whilst avoiding morbidity and availability issues encountered with autografts and potential disease transmission associated with allografts and xenografts.

#### 7.3 Sutures and screws

Absorbable sutures are too weak to provide sufficient mechanical resilience [324]; thus nonabsorbable suture are the primary surgical repair option for tendon repair [325] and are the only option in cases involving the flexor tendons of the hand [326]. To-date, numerous suture techniques have been adopted for tendon repair, including lateral trap, end-wave, locking, grasping, Bunnell, Mason-Allen and modified Kessler [324, 326, 327], with the modified Kessler being the most popular. Commonly used materials for suturing tendons include stainless steel, catgut, polypropylene, polyethylene, polyesters, nylon, silicone, silk and collagen coated versions of some of them. These materials are produced either in mono- or multi-filament versions and may or may not be braided [326]. Traditional sutures involve end-to-end repair to bridge the gap at rupture [327]. Multi-strand (primarily four-strand [328]) locking configuration are extensively used in clinical practice. Although locking loops prevent sutures from pulling, they are often associated with suture breakage and tendon rupture due to pulling of the suture at the sutured site [329]. Given that knots adversely affect gliding and locking configurations negatively impact on vascularity, barbed sutures have gained more attention as they ensure equal distribution of load throughout the intratendinous suture length [330-334]. Despite the significant work in the field, there is still no gold standard.

Suitable tendon healing will not occur for gaps greater that 5 mm [335, 336]. To this end, improvements in the fixation methods are at the forefront of clinical research to reduce the bone tunnel enlargement for tendon [337, 338] and ligament [339, 340]. Interferential screws, bioabsorbable or metalling in origin [341], are considered as the gold standard for tendon-to-bone fixation and for ligament reconstruction [342-344]. However, recent data demonstrate viscoelastic deformation, which causes widening of the bone tunnel into which the tendon is inserted, resulting in slippage of the tendon [345]. Primary fixation is employed to act as an interlock between the screw and the graft [346]. Recent data demonstrate improved strength fixation by as much as 30% by simply ensuring that the screw is shorter than the graft [337, 347]. Nonetheless, numerous complications and adverse effects have been reported in clinical setting (e.g. intra-operative fracture, intra-articular complications, extra-articular abscesses) [348], clearly indicating that further research is necessary to elucidate the underlying mechanisms of tendon-to-bone healing and to translate safe and therapeutic interventions [349].

#### 7.4 Bottom-up approached for tendon repair based on natural in origin scaffolds

To-date, numerous biopolymers have been assessed for tendon repair, with variable degree of efficacy. Among them, collagen-based devices, in many physical forms (e.g. sponges, films, fibres), appear to be the favourite raw material [124, 127]. Advancements in engineering, chemistry and biology have made available numerous technologies that allow fabrication of hierarchical threedimensional scaffolds that closely imitate native tendon architectural features and mechanical properties, whilst enabling localised and sustained delivery of therapeutics [350]. Collagen sponges, for example, with or without aligned tracks and loaded with GAGs, growth factors and various cell populations have demonstrated enhanced cell motility and phenotype maintenance in vitro and increased collagen expression levels in small animal models [351-355]. However, such scaffold conformations cannot provide adequate mechanical resistance, in such a high mechanical demand environment [356]. Using a wet extrusion system, micro-scale collagen fibres (Figure 3) were first produced in late 1970's and since then numerous papers have demonstrated that this process gives rise to fibres with ultrastructure characteristics, physical and mechanical properties similar to native tendon [257, 259, 357-359]. Further in vitro analysis demonstrated that such materials, largely attributed to their surface features, not only facilitate bidirectional cell alignment, but also maintain tenogenic phenotype in vitro [360]. Further, preclinical experimentation in peripheral nerve repair and in tendon small and large animal models enhanced the clinical potential of these fibres, as judged by improved structural alignment and biomechanics [361-363]. Using an isoelectric focusing setup, aligned collagen fibres have been produced with ultrastructural characteristics and physical properties similar to native tendon [364, 365]. Of significant importance are in vitro data that have been obtained using these materials. When their potential for spinal cord injuries was assessed, it became apparent that such materials not only promote directional neurite guidance, but also overcome inhibition by myelin associated glycoprotein [366]. In a tendon setting, these collagen fibres have been shown to promote bidirectional alignment and migration of tendon derived cells and to differentiate human BMSCs towards tenogenic lineage, even in the absence of biological signals [367, 368]. Combinations of fibrous scaffolds that offer mechanical resilience and hydrogels systems that offer cell retention capacity have demonstrated improved biomechanics and functionality in preclinical models [369, 370]. Whether such systems will reach the clinic, remains to be seen, given the notable lack of extensive in vivo data. Further, appropriate regulatory framework should be implemented to allow such systems to enter the clinic.

Silk-based sutures have been extensively used to treat ruptured tendon due to their high mechanical properties and excellent biodegradability [371-375]. *In vitro* data have demonstrated that silk-based scaffolds support adherence, expansion and differentiation of human BMSCs towards tenogenic lineage, as assessed by the expression levels of collagen types I and III and tenascin-C [376]. Silk

fibres functionalised with peptide moieties [377], HA [378] and chondroitin sulphate / collagen [379] have been shown to maintain tendon function in vitro, to increase blood vessel formation and cellular infiltration, to promote formation for dense collagen fibres and to encourage overall tendon healing over control counterparts in a canine patellar tendon defect model and to a rabbit cruciate ligament defect model. Mechanical loading of aligned silk scaffolds loaded with BMSCs resulted in increased production of collagen type I, collagen type III and tenascin C, when compared to not aligned and not mechanically stimulated counterparts [380]. Further large animal model studies have demonstrated that silk / BMSCs composites induced functional ACL replacement, with silk degrading in a similar rate as the neotissue was formed [381]. However, complete replacement based on silk did not yield a functional therapy [382], which, in addition to the concerns of allergic reaction, have restricted its use in regenerative medicine [373]. To a smaller extent, chitosan / alginate composites have been assessed for tendon repair, with in vitro data demonstrating adherence of rabbit tendon fibroblast and increased collagen type I expression and mechanical properties [383]. Preclinical data of chitosan and chitosan / HA scaffolds have demonstrated enhanced tissue-specific ECM production and improved mechanical strength, as compared to the control treatments [384-387]. Polyhydroxyalkanoates, natural polymers produced by bacteria, have also shown great potential in tissue engineering [388]. Specifically to tendon repair, such materials have shown improved mechanical properties, improved functionality and minimal inflammatory response in small animal studies over 40 days implantation in an Achilles defect model [389]. The batch-to-batch variability of natural biomaterials and their susceptibility to various sterilisation methods [390] have triggered investigation into the potential of synthetic biomaterials for tendon repair and regeneration.

#### 7.5 Bottom-up approached for tendon repair based on synthetic in origin scaffolds

Absorbable and not absorbable synthetic materials are used extensively in tendon repair, as they can be produced reproducibly with structural, physical and mechanical properties similar to the tissue to be replaced [391]. Unfortunately, non-degradable devices have failed to deliver functional repair. A polyester-based device, for example, although it has been used extensively in clinical practice, clinical data demonstrate inferior to tissue grafts repair that is often associated with laxity in joints. engraftment tunnel enlarging and, in some cases, complete rupture [392-394]. Similarly, although polypropylene-based devices have demonstrated superior mechanical properties to control treatments, histological evaluation revealed poor tissue integration, evidenced by the formation of a disordered fibrous capsule [395]. Dacron (polyethylene terephthalate) prosthesis, although it has demonstrated acceptable mechanical properties, functional regeneration and neotissue formation was not achieved [396, 397]; however HA / chitosan coating demonstrated good histological scores in a rabbit articular tendon model [398]. Carbon fibres have exhibited clinically acceptable mechanical and structural properties, promoted extrinsic and intrinsic cellular activity and ultimately a functional neotissue formation, leading to long-term tissue integration and healing [399, 400]. However, the potential side effects of carbon have limited their further development [401-403]. These results gave rise to degradable-based substitutes for tendon repair.

Among the manifold polymers, PLGA based scaffolds have been extensively assessed in tendon repair. With respect to fabrication methods, electro-spinning (Figure 4) appears to be the method of choice, as aligned nano- to micro-fibrous scaffolds can be produced with mechanical and structural features similar to the tissue to be replaced and with ability to control permanently differentiated and stem cell fate *in vitro*; to locally deliver in a controlled manner pharmacological agents, biological molecules and cells at the side of injury; and to enhance directional neotissue formation [404-409]. Although electro-spun collagen scaffolds have demonstrated improved neotissue alignment and mechanical properties, over control counterparts in a rabbit Achilles tendon model [410] the realisation that the use of fluoro-alcohols denatures the triple helical confirmation of collagen [411, 412] has reduced further investigations.

Although tendon-like tissues have been generated *in vitro* using TCs grown on PLGA electro-spun fibres, the *de novo* formed tissue was found to be significantly thinner and weaker than a natural tendon control [413]. However, mechanical stimulation of human foetal extensor tendon TCs loaded on electro-spun PLGA fibres promoted collagen alignment, produced a more mature collagen structure and created a stronger *de novo* tissue [414], suggesting that mechanical stimulation might be an optimal *in vitro* niche for engineering functional tendon equivalents *ex vivo*. Porcine dermal fibroblasts and TCs loaded on PLGA electro-spun fibres have been shown to promote tenogenic function *in vitro* and improved healing, as evidenced by improved gross

morphology, histological analysis and biomechanical properties, *in vivo* [413-416]. In conjugation with BMSCs, electro-spun PLGA scaffolds have demonstrated suppression of lymphocytes *in vitro* and improved biomechanical properties and acceptable integration into the native tendon tissue [417]. GDF-5 loaded PLGA electro-spun scaffolds supported growth and promoted tenogenic differentiation of rat ADSCs [418]. Further *in vitro* studies using bFGF loaded PLGA electro-spun scaffolds have demonstrated enhanced BMSC proliferation and tendon differentiation, as evidenced by increased expression collagen type I and tenascin-C [419], whilst *in vivo* studies have shown greater vascularisation, higher histological scores and superior mechanical properties to naturally healed and non-functionalised counterparts [420]. A more complex approach based on PLGA electro-spun scaffolds and a fibrin gel loaded with ADSCs and PDGF- $\beta\beta$  demonstrated improved healing over standard controls [421]. Electro-spun poly- $\varepsilon$ -caprolactone (PCL) scaffolds coated with tendon-derived ECM promoted ADSC attachment, homogeneous distribution within the scaffolds and expression of tendon specific markers [422]. Functionalisation using HA has enabled integration of PCL electro-spun scaffolds into a chicken foot tendon model, whilst preventing post-surgical adhesions [423].

Lithography-based technologies have also been used as means to produce anisotropic substrates for tendon repair (Figure 5). Such micro-grooved substrates have been shown to maintain TC phenotype *in vitro*, as indicated by collagen type I and tenomodulin expression; most importantly, these micro-grooved substrates were shown to recapitulate the lost tenogenic phenotype of TCs [424]. Given the literally unlimited number of possible topographies, a recent study developed imprinted substrates using tendon slices as template; the produced substrates, following collagen type I coating, supported tenogenic differentiation of BMSCs [425]. To-date, there is no *in vivo* work of such substrates in a tendon model.

Despite the huge progress that has been achieved to-date, synthetic materials are yet to meet the requirements for functional tendon tissue remodelling [426]. The use of PLGA and PCL has been problematic, with *in vitro* data showing poor tendon cell adhesion, reduced proliferation rate and phenotypic drift [360, 427]; with preclinical *in vivo* data showing poor cellular infiltration and mechanical properties compared to controls [428]; and with clinical evaluations showing problems with cell lysis, anchor failure, macrophage stimulation and allergic responses [429, 430]. This high failure rate has been attributed to their hydrophobic nature and their lack of cell recognition signals that prevents cell attachment [391, 431-434]. To this end, scaffold-free therapies based on the principles of tissue engineering by self-assembly / cell-sheet technology are slowly, but surely, gaining more scientific and technological interest.

## 7.6 Tissue engineering by self-assembly therapies

Tissue engineering by self-assembly or cell-sheet tissue engineering has been extensively studied over the years for various clinical targets [435-439]. The rationale of this approach is based on the fact that cells can create their own tissue-specific ECM, bypassing the need for artificial devices and their shortfalls. The first in vitro study demonstrated that such cellular assemblies resemble the nonlinear behaviour of immature tendons [440]. Using rat TSCs, a neotendon tissue was formed that after eight weeks in a rat patellar tendon defect model showed marked improvement in histological scores, tissue alignment and mechanical properties, as compared to naturally healed control [441]. Unfortunately, such technologies require prolonged culture time to develop an implantable device with sufficient strength, which is often associated with phenotypic drift and cellular senescence [442]. To this end, the use of cell-sheets combined with biodegradable meshes [443] or tissue grafts [444] has been advocated as means to create a mechanically stable implantable device, with the latter showing better results than the graft or the cells alone intervention in a rabbit model. An alternative strategy that bypasses the use of the carrier systems and their limitations is based on the principles of macromolecular crowding [445-448]. Indeed, the addition of negatively charged macromolecules in the culture media (Figure 6), by imitating the naturally crowded in vivo context, dramatically accelerates the conversion of procollagen to collagen, resulting in a 30- to 80fold increase in tissue-specific ECM deposition. Using human TCs, a rich in ECM and cohesive cell-sheet was produced with intact cell-cell and cell-ECM junctions as early as 6 days in culture, without any negative effects in TC functions [449]. Despite these advancements, a complete threedimensional tendon-equivalent has yet to be developed.

### 8. Conclusions

It is undeniable that recent advancements in engineering, chemistry and biology have made available numerous technologies that can be utilised for tendon repair and regeneration. Two- and three-dimensional fabrication technologies have realised tissue facsimiles that closely imitate the properties of native tendon tissue, control cellular fate *in vitro* and promote directional neotissue formation *in vivo*. Improved processing, decellularisation and recellularisation strategies reinstate the potential of allogeneic and xenogeneic tissue grafts. Novel chemistries allow for localised and sustained delivery of pharmaceuticals, biologics and cells at the side of injury.

However, none of the current therapies restores tendon function to the state prior to injury, as every single therapy has its distinct failure modes, and all fail to closely match the native tendon biomechanics over prolonged period of time *in vivo*. Further, knot improving and stress relieving mounting strategies should be developed to enhance functional regeneration. Strategies that provide continuous and sufficient mechanical properties and gradients of stress distributions from bone attachment surfaces, seen in native ligaments, will likely offer decreased failure rates.

It is also imperative to understand the *in vivo* milieu prior to injury and the biological events that take place thereafter. Only then we will be in position to develop clinically relevant carrier systems loaded with efficacious pharmaceuticals / biologics and sufficient density of suitable viable cells that will effectively interact with the host and promote functional tendon repair, remodelling and regeneration, avoiding scar and foreign body responses are also likely to succeed.

Overall, systems that will provide sufficient mechanical integrity, biological / biochemical cues and suitable cell types will continue to be at the forefront of academic, industrial and clinical research, promising to deliver functional regeneration through rehabilitation in the years to come.

## 9. Acknowledgements

The authors would like to thank Maciek Doczyk for the preparation of the graphical abstract, Figure 1 and Figure 5. This work is supported by the: EU FP7/2007-2013, Marie Curie, IAPP award, part of the People programme, Tendon Regeneration Project (Grant Agreement Number: 251385) to D.Z.; EU FP7/2007-2013, NMP award, Green Nano Mesh Project (Grant Agreement Number: 263289) to D.Z.; Science Foundation Ireland (Project Number: SFI\_09-RFP-ENM2483) to D.Z.; Health Research Board, Health Research Awards Programme, under the grant agreement number HRA\_POR/2011/84 to D.Z.; Enterprise Ireland, Collaborative Centre for Applied Nanotechnology (Project No: CCIRP-2007-CCAN-0509), under the Irish Government's National Development Plan 2007-2013 to D.Z.; Teagasc, Department of Agriculture, Food and Marine, FIRM / RSF / CoFORD (Project Number: 11-F-043) to D.Z. We thank NW Tex Net for hosting C.N.M.R and Vornia Biomaterials for hosting D.Z.

# 10. Tables

Table 1: Common injuries presented in human an	d equine subjects,	provided along with curren	t treatment strategies and respective limitations.
--	--------------------	----------------------------	--

Species	Tendon Injury	Treatment	Limitation	Ref	
Human	<b>H</b>	Immobilisation (splint)	Scar tissue leads to loss / reduction of motion. Joint stiffness is often experienced.		
	Hand extensor / flexor tendon	Steroid injection	Serious doubts over effectiveness.	[28, 450, 451]	
		Open Surgery: Kessler stitch	Re-rupture rate following surgery is as high as 4 to 18% worldwide.		
	Achilles tendon (rupture)	Cast immobilisation	Susceptible to re-rupture at a rate of about 11%.		
		Functional cast	Low re-rupture rate of 1-2%, but high complication rate of 12.5%.		
		Open Surgery: Kessler stitch	High re-rupture rate of 8% and nerve injury of 13%.	[23, 452, 453]	
		Tissue grafts	Failures seen at tissue intersect points.		
		Biomaterial repair	Inadequate mechanical strength and foreign body response.		
	Rotator cuff (tear)	Steroid injection	Up to 40% failure rates have been reported.	[2, 454-458]	

		Open surgery: Decompression	Often associated with deltoid dysfunction		
		and debridement	and postoperative pain.		
		Piometerial renair	Inadequate mechanical strength and foreign		
		Biomaterial repair	body response.		
	Patellar tendon (tear)	End-to-end suture	10 out of the 13 repairs are effective.	[459]	
		Tissue grafts	Limited availability, pain at donor site.		
	ACL (rupture)	Tissue grafts	Up to 13% re-rupture rate.	[460]	
		Cold therapy & compression	23 to 67% will re-injure their tendons within	hin [43_46]	
		bandaging	2 years of the original injury.		
	Superficial digital flexor tendon injury	Immobilisation (splint)	Associated with stiffness and fibrosis.	[07, 70]	
		Autologous cell therapy	Questionable cell survival / localisation.	[44, 461, 462]	
Equine	Deep digital flexor tendon injury	Conservative treatment (rest and reduced activity)	Return to exercise is not recommended.	[51, 52]	
	Digital extensor tendon laceration	Three-looppulleytenorrhaphy technique	Adhesions and septic tenosynovitis are common complications.	[54]	
	Suspensory ligament	Conservative treatment (rest and reduced activity)	Return to exercise is not recommended for several months.	[463, 464]	

	Shock wave therapy	Evidence of disorganised tissue. Not suitable in severe cases.	[465, 466]
	PRP treatment	No standardised treatment protocol.	[467-469]

Healing Mechanism	Cell Population	Location	Morphology	Dimensions (µm)	Ref
Intrinsic Healing	Tenocytes	Throughout tendon, surrounding collagen fibrils	Elongated, spindle shape	Width: 8 – 20 Length: < 300	[470]
	Tenoblasts	Throughout tendon, surrounding collagen fibrils	Polygonal	Width: 8 – 20 Length: 20 – 70	[62]
	Tendon stem cells	Throughout tendon	Species, tendon, development stage dependent morphology (e.g. cobblestone, square, round, spindle)	Width: 20 – 30 Length: 20 – 30	[65, 66, 471]
Extrinsic Healing	Chondrocytes	Close to bone junction	Polygonal	Width: 10 – 15 Length: 10 – 15	[472]
	Vascular endothelial cells	Surrounding vascular network	Cobblestone / square	Width: 8 – 12 Length: 8 – 12	[473]
	Synovial cells	Tendon sheath	Elongated, with extended cytoplasmic projections	Width: 10 – 50 Length: ≤ 200	[474, 475]
	Smooth muscle cells	Musculotendon junction, internal and external tendon capillaries	Cobblestone / square	Width: 20 – 30 Length: 20 – 30	[64, 476]
	Perivascular cells	In the walls of internal and external tendon capillaries	Elongated, spindle shape	Width: $\leq 50$ Length: $\leq 300$	[68, 69]
	Mesenchymal stem	Migrate from surrounding tissues,	Elongated, spindle shape	Width: 10 – 20	[70, 477]

# **Table 2:** Cellular composition and characteristics of tendon tissue.

cells	especially bone marrow		Length: 100 – 300	
Adipose derived stem	Surrounding fat pads	Elongated, spindle shape	Width: 10 – 20	[72]
cells			Length: 100 – 300	

<b>Tissue / Biomaterial</b>	Stress (MPa)	Strain (%)	Modulus (MPa)	Reference
Equine digital flexor / extensor	65 - 160	12 – 22	613 – 1220	[478-480]
Human Achilles	29 - 86	4 – 22	1.9 - 822	[481-483]
Human rotator	14 – 45	1 – 11	14 - 629	[484-486]
Human patellar	5 - 65	5 – 15	1500 - 1800	[487, 488]
Human Achilles graft	16	1	201	[489]
Human patellar graft	26 - 95	13 – 31	191 - 660	[490]
Human tibialis graft	81 – 105	13 - 40	1 – 905	[491-493]
Collagen-based materials	1 – 355	1 - 60	3 - 4272	[257, 359, 494-497]
Silk-based materials	500 - 972	4 - 20		[373]
Synthetic micro-fibres	435 - 840	22 - 45		[498]
Synthetic nano-fibres	1 – 474	1 – 11	2 - 14	[171, 410, 422, 499-502]

## **Table 3:** Mechanical properties of native tendon tissues and tendon substitutes
## 11. Figures

Graphical Abstract: Injectable systems, anisotropic materials and tissue engineering by self-assembly therapies for human and equine injuries.





Figure 1: Spatial distribution of cellular and matrix components in tendons.





**Figure 3:** Transmission electron microscopy revealed that extruded collagen fibres exhibit the characteristic quarter-staggered periodicity of collagen, in addition to a high order axial alignment, parallel to the fibre axis (a). This axial alignment is responsible for undulation and crevices that run parallel to the longitudinal axis of the fibre (b). These surface characteristics induce parallel to the fibre axis tenocyte elongation as early as 24h in culture (c). A fibre bundle, suitable for tendon repair, is formed, when several fibres are put together (d).



**Figure 4:** Using a rotating collector, aligned electro-spun fibres can be produced (a). This anisotropic topography maintains the physiological elongated tenocyte morphology in culture (b). Such materials can be used as tendon sheaths (c) or, when rolled, as a full tendon replacement device.



**Figure 5:** Using imprinting technologies, substrates with precise topographical features, ranging from nano- to micro level, can be created (a and b). Among them, anisotropic substrates (c) have been shown to maintain physiological TC morphology (d).



**Figure 6:** Macromolecular crowding, the addition of inert macromolecules in the culture media, dramatically accelerates the conversion of procollagen to collagen and the production of a rich in ECM cell layer (a). In tenocyte culture, among others, significant increase in collagen type I (c) and collagen type III (e) deposition has been observed, as compared to the non-crowded counterparts (b and d respectively).



## 12. References

[1] S. Abbah, K. Spanoudes, T. O'Brien, A. Pandit, D. Zeugolis, Assessment of stem cell carriers for tendon tissue engineering in pre-clinical models, Stem Cell Research & Therapy, 5 (2014) 38.

[2] U.G. Longo, A. Lamberti, N. Maffulli, V. Denaro, Tendon augmentation grafts: A systematic review, British Medical Bulletin, 94 (2010) 165-188.

[3] D. Zeugolis, J. Chan, A. Pandit, Tendons: Engineering of functional tissues, in: Pallua, N., Suscheck, C. (Eds.) Tissue Engineering, Springer, Berlin, Heidelberg, 2011, pp. 537-572.

[4] R.B. Williams, L.S. Harkins, C.J. Hammond, J.L. Wood, Racehorse injuries, clinical problems and fatalities recorded on British racecourses from flat racing and National Hunt racing during 1996, 1997 and 1998, Equine Veterinary Journal, 33 (2001) 478-486.

[5] A.G.L. Alves, A.A. Stewart, J. Dudhia, Y. Kasashima, A.E. Goodship, R.K.W. Smith, Cellbased therapies for tendon and ligament injuries, Veterinary Clinics of North America-Equine Practice, 27 (2011) 315-333.

[6] J.B. Tang, Tendon injuries across the world: Treatment, Injury, 37 (2006) 1036-1042.

[7] N. Maffulli, Rupture of the Achilles tendon, Journal of Bone and Joint Surgery, 81 (1999) 1019-1036.

[8] F.R. Noyes, P.A. Mooar, D.S. Matthews, D.L. Butler, The symptomatic anterior cruciatedeficient knee. Part I: The long-term functional disability in athletically active individuals, J Bone Joint Surg Am, 65 (1983) 154-162.

[9] H. Roos, M. Ornell, P. Gardsell, L.S. Lohmander, A. Lindstrand, Soccer after anterior cruciate ligament injury -- An incompatible combination? A national survey of incidence and risk factors and a 7-year follow-up of 310 players, Acta Orthop Scand, 66 (1995) 107-112.

[10] M. Astrom, A. Rausing, Chronic Achilles tendinopathy. A survey of surgical and histopathologic findings, Clin Orthop Relat Res, 316 (1995) 151-164.

[11] T. Movin, A. Gad, F.P. Reinholt, C. Rolf, Tendon pathology in long-standing achillodynia. Biopsy findings in 40 patients, Acta Orthop Scand, 68 (1997) 170-175.

[12] T. Hashimoto, K. Nobuhara, T. Hamada, Pathologic evidence of degeneration as a primary cause of rotator cuff tear, Clin Orthop Relat Res, 415 (2003) 111-120.

[13] K.M. Khan, N. Maffulli, B.D. Coleman, J.L. Cook, J.E. Taunton, Patellar tendinopathy: Some aspects of basic science and clinical management, Br J Sports Med, 32 (1998) 346-355.

[14] H.G. Potter, J.A. Hannafin, R.M. Morwessel, E.F. DiCarlo, S.J. O'Brien, D.W. Altchek, Lateral epicondylitis: Correlation of MR imaging, surgical, and histopathologic findings, Radiology, 196 (1995) 43-46.

[15] F. Benazzo, M. Mosconi, N. Maffulli, Hindfoot tendinopathies in athletes, in: Maffulli, N., Renstro, M., Leadbetter, W. (Eds.) Tendon injuries basic science and clinical medicine Springer, London, 2005.

[16] T. Raatikainen, J. Karpakka, J. Puranen, S. Orava, Operative treatment of partial rupture of the patellar ligament. A study of 138 cases, Int J Sports Med, 15 (1994) 46-49.

[17] K.M. Khan, J.L. Cook, F. Bonar, P. Harcourt, M. Astrom, Histopathology of common tendinopathies. Update and implications for clinical management, Sports Med, 27 (1999) 393-408.

[18] C.E. Nichols, Patellar tendon injuries, Clin Sports Med, 11 (1992) 807-813.

[19] N. Maffulli, V. Barrass, S.W. Ewen, Light microscopic histology of achilles tendon ruptures. A comparison with unruptured tendons, Am J Sports Med, 28 (2000) 857-863.

[20] H. Alfredson, L. Ohberg, S. Forsgren, Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections, Knee Surgery, Sports Traumatology, Arthroscopy, 11 (2003) 334-338.

[21] H. Alfredson, L. Ohberg, Sclerosing injections to areas of neo-vascularisation reduce pain in chronic Achilles tendinopathy: A double-blind randomised controlled trial, Knee Surgery, Sports Traumatology, Arthroscopy, 13 (2005) 338-344.

[22] K.M. Khan, J.L. Cook, P. Kannus, N. Maffulli, S.F. Bonar, Time to abandon the "tendinitis" myth, British Medical Journal, 324 (2002) 626-627.

[23] J.D. Rees, A.M. Wilson, R.L. Wolman, Current concepts in the management of tendon disorders, Rheumatology, 45 (2006) 508-521.

[24] J.B. Tang, Clinical outcomes associated with flexor tendon repair, Hand Clin, 21 (2005) 199-210.

[25] A. Chesney, A. Chauhan, A. Kattan, F. Farrokhyar, A. Thoma, Systematic review of flexor tendon rehabilitation protocols in zone II of the hand, Plast Reconstr Surg, 127 (2011) 1583-1592.

[26] A. Higgins, D.H. Lalonde, M. Bell, D. McKee, J.F. Lalonde, Avoiding flexor tendon repair rupture with intraoperative total active movement examination, Plast Reconstr Surg, 126 (2010) 941-945.

[27] M.J. Saldana, J.A. Chow, P. Gerbino, 2nd, P. Westerbeck, T.G. Schacherer, Further experience in rehabilitation of zone II flexor tendon repair with dynamic traction splinting, Plast Reconstr Surg, 87 (1991) 543-546.

[28] C.J. Dy, A. Daluiski, H.T. Do, A. Hernandez-Soria, R. Marx, S. Lyman, The epidemiology of reoperation after flexor tendon repair, Journal of Hand Surgery-American Volume, 37A (2012) 919-924.

[29] S.L. James, B.T. Bates, L.R. Osternig, Injuries to runners, Am J Sports Med, 6 (1978) 40-50.

[30] J. Garrick, R. Requa, ACL injuries in men and women - How common are they?, in: Griffin, L.(Ed.) Prevention of noncontact ACL injuries, American Academy of Orthopedic Surgeons, Rosemont, 2001.

[31] R.A. Drongowski, A.G. Coran, E.M. Wojtys, Predictive value of meniscal and chondral injuries in conservatively treated anterior cruciate ligament injuries, Arthroscopy, 10 (1994) 97-102.
[32] S.L. Buckley, R.L. Barrack, A.H. Alexander, The natural history of conservatively treated

partial anterior cruciate ligament tears, Am J Sports Med, 17 (1989) 221-225.

[33] P. Kannus, M. Jarvinen, Conservatively treated tears of the anterior cruciate ligament. Long-term results, J Bone Joint Surg Am, 69 (1987) 1007-1012.

[34] K.L. Markolf, J.S. Mensch, H.C. Amstutz, Stiffness and laxity of the knee -- The contributions of the supporting structures. A quantitative in vitro study, J Bone Joint Surg Am, 58 (1976) 583-594.

[35] F.H. Fu, C.H. Bennett, C. Lattermann, C.B. Ma, Current trends in anterior cruciate ligament reconstruction. Part 1: Biology and biomechanics of reconstruction, Am J Sports Med, 27 (1999) 821-830.

[36] D. Amiel, J.B. Kleiner, R.D. Roux, F.L. Harwood, W.H. Akeson, The phenomenon of "ligamentization": Anterior cruciate ligament reconstruction with autogenous patellar tendon, Journal of Orthopeadic Research, 4 (1986) 162-172.

[37] D.L. Butler, Kappa Delta Award paper. Anterior cruciate ligament: Its normal response and replacement, Journal of Orthopeadic Research, 7 (1989) 910-921.

[38] R.T. Ballock, S.L. Woo, R.M. Lyon, J.M. Hollis, W.H. Akeson, Use of patellar tendon autograft for anterior cruciate ligament reconstruction in the rabbit: a long-term histologic and biomechanical study, Journal of Orthopeadic Research, 7 (1989) 474-485.

[39] B.D. Beynnon, R.J. Johnson, H. Toyama, P.A. Renstrom, S.W. Arms, R.A. Fischer, The relationship between anterior-posterior knee laxity and the structural properties of the patellar tendon graft. A study in canines, Am J Sports Med, 22 (1994) 812-820.

[40] G.L. Pinchbeck, P.D. Clegg, C.J. Proudman, K.L. Morgan, N.P. French, A prospective cohort study to investigate risk factors for horse falls in UK hurdle and steeplechase racing, Equine Veterinary Journal, 36 (2004) 595-601.

[41] R.K.W. Smith, H.L. Birch, S. Goodman, D. Heinegard, A.E. Goodship, The influence of ageing and exercise on tendon growth and degeneration - Hypotheses for the initiation and prevention of strain-induced tendinopathies, Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology, 133 (2002) 1039-1050.

[42] C.S. Avella, E.R. Ely, K.L.P. Verheyen, J.S. Price, J.L.N. Wood, R.K.W. Smith, Ultrasonographic assessment of the superficial digital flexor tendons of National Hunt racehorses in training over two racing seasons, Equine Veterinary Journal, 41 (2009) 449-454.

[43] C.T. Thorpe, P.D. Clegg, H.L. Birch, A review of tendon injury: Why is the equine superficial digital flexor tendon most at risk?, Equine Veterinary Journal, 42 (2010) 174-180.

[44] L.E. Richardson, J. Dudhia, P.D. Clegg, R. Smith, Stem cells in veterinary medicine - Attempts at regenerating equine tendon after injury, Trends in Biotechnology, 25 (2007) 409-416.

[45] B.A. Dowling, A.J. Dart, D.R. Hodgson, R.K.W. Smith, Superficial digital flexor tendonitis in the horse, Equine Veterinary Journal, 32 (2000) 369-378.

[46] E.R. Ely, C.S. Avella, J.S. Price, R.K.W. Smith, J.L.N. Wood, K.L.P. Verheyen, Descriptive epidemiology of fracture, tendon and suspensory ligament injuries in National Hunt racehorses in training, Equine Veterinary Journal, 41 (2009) 372-378.

[47] C.B. O'Sullivan, Injuries of the flexor tendons: Focus on the superficial digital flexor tendon, Clinical Techniques in Equine Practice, 6 (2007) 189-197.

[48] S. Adams, J. Fessler, Proximal check desmotomy / Percutaneous tendon splitting, in: Adams,S., JF, F. (Eds.) Atlas of Equine Surgery, Saunders, Philadelphia, 2000, pp. 353-357.

[49] L.A. Fortier, R.K.W. Smith, Regenerative medicine for tendinous and ligamentous injuries of sport horses, Veterinary Clinics of North America-Equine Practice, 24 (2008) 191-201.

[50] R. Smith, P. Webbon, Musculoskeletal system, in: Colahan, P., Mayhew, I., Merritt, A., Moore, J. (Eds.) Equine Medicine and Surgery, Mosby, St Louis 1999, pp. 1358-1683.

[51] L. Gaschen, D.J. Burba, Musculoskeletal injury in thoroughbred racehorses correlation of findings using multiple imaging modalities, Veterinary Clinics of North America-Equine Practice, 28 (2012) 539-561.

[52] M.R.W. Smith, I.M. Wright, R.K.W. Smith, Endoscopic assessment and treatment of lesions of the deep digital flexor tendon in the navicular bursae of 20 lame horses, Equine Veterinary Journal, 39 (2007) 18-24.

[53] H. Jann, M. Blaik, R. Emerson, M. Tomioka, L. Stein, D. Moll, Healing characteristics of deep digital flexor tenorrhaphy within the digital sheath of horses, Veterinary Surgery, 32 (2003) 421-430.

[54] R.L. Smith, D.J. Murphy, R.E. Day, G.D. Lester, An ex vivo biomechanical study comparing strength characteristics of a new technique with the three-loop pulley for equine tenorrhaphy, Veterinary Surgery, 40 (2011) 768-773.

[55] C.L. Crowson, H.W. Jann, L.E. Stein, L.P. Claypool, H.D. Moll, M.A. Blaik, Quantitative effect of tenorrhaphy on intrinsic vasculature of the equine superficial digital flexor tendon, American Journal of Veterinary Research, 65 (2004) 279-282.

[56] H. Jann, C. Pasquini, Wounds of the distal limb complicated by involvement of deep structures, Veterinary Clinics of North America-Equine Practice, 21 (2005) 145-165.

[57] C. Kikker-Head, Musculoskeletal system, in: Colahan, P., Mayhew, I., Merritt, A., Moore, J. (Eds.) Equine Medicine and Surgery, Mosby, St Louis, 1999, pp. 1683-1685.

[58] P. Kannus, Structure of the tendon connective tissue, Scandinavian Journal of Medicine & Science in Sports, 10 (2000) 312-320.

[59] M. Benjamin, E. Kaiser, S. Milz, Structure-function relationships in tendons: A review, Journal of Anatomy, 212 (2008) 211-228.

[60] R. Strocchi, V. Depasquale, S. Guizzardi, P. Govoni, A. Fachini, M. Raspanti, M. Girolami, S. Giannini, Human Achilles tendon - Morphological and morphometric variations as a function of age, Foot & Ankle1991, pp. 100-104.

[61] M. Kjaer, Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading, Physiological Reviews, 84 (2004) 649-698.

[62] F.S. Chuen, C.Y. Chuk, W.Y. Ping, W.W. Nar, H.L. Kim, C.K. Ming, Immunohistochemical characterization of cells in adult human patellar tendons, Journal of Histochemistry & Cytochemistry, 52 (2004) 1151-1157.

[63] E. Ippolito, P.G. Natali, F. Postacchini, L. Accinni, C. Demartino, Morphological, immunochemical, and biochemical - Study of rabbit Achillies-tendon at various ages, Journal of Bone and Joint Surgery-American Volume, 62 (1980) 583-598.

[64] P. Sharma, N. Maffulli, Biology of tendon injury: Healing, modeling and remodeling, Journal of Musculoskeletal & Neuronal Interactions, 6 (2006) 181-190.

[65] Y. Bi, D. Ehirchiou, T.M. Kilts, C.A. Inkson, M.C. Embree, W. Sonoyama, L. Li, A.I. Leet, B.M. Seo, L. Zhang, S. Shi, M.F. Young, Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche, Nature Medicine, 13 (2007) 1219-1227.

[66] J. Zhang, J.H. Wang, Characterization of differential properties of rabbit tendon stem cells and tenocytes, BMC Musculoskeletal Disorders, 11 (2010) 10.

[67] P.P. Lui, K.M. Chan, Tendon-derived stem cells (TDSCs): From basic science to potential roles in tendon pathology and tissue engineering applications, Stem Cell Reviews, 7 (2011) 883-897.

[68] H. Tempfer, A. Wagner, R. Gehwolf, C. Lehner, M. Tauber, H. Resch, H.C. Bauer, Perivascular cells of the supraspinatus tendon express both tendon- and stem cell-related markers, Histochemistry and Cell Biology, 131 (2009) 733-741.

[69] J.A. Cadby, E. Buehler, C. Godbout, P.R. van Weeren, J.G. Snedeker, Differences between the cell populations from the peritenon and the tendon core with regard to their potential implication in tendon repair, PLoS One, 9 (2014) e92474.

[70] C. Gittel, W. Brehm, J. Burk, H. Juelke, C. Staszyk, I. Ribitsch, Isolation of equine multipotent mesenchymal stromal cells by enzymatic tissue digestion or explant technique: Comparison of cellular properties, BMC Veterinary Research, 9 (2013) 221.

[71] P. Theobald, G. Bydder, C. Dent, L. Nokes, N. Pugh, M. Benjamin, The functional anatomy of Kager's fat pad in relation to retrocalcaneal problems and other hindfoot disorders, Journal of Anatomy, 208 (2006) 91-97.

[72] M. Wickham, G. Erickson, J. Gimble, T. Vail, F. Guilak, Multipotent stromal cells derived from the infrapatellar fat pad of the knee, Clin Orthop Relat Res, 412 (2003) 196-212.

[73] G.D. Pins, D.L. Christiansen, R. Patel, F.H. Silver, Self-assembly of collagen fibers. Influence of fibrillar alignment and decorin on mechanical properties, Biophysical Journal, 73 (1997) 2164-2172.

[74] F. Silver, D. Christiansen, P. Snowhill, Y. Chen, W. Landis, The role of mineral in the storage of elastic energy in turkey tendons, Biomacromolecules, 1 (2000) 180-185.

[75] C. Widmer, J.M. Gebauer, E. Brunstein, S. Rosenbaum, F. Zaucke, C. Drogemuller, T. Leeb, U. Baumann, Molecular basis for the action of the collagen-specific chaperone Hsp47/SERPINH1 and its structure-specific client recognition, Proceedings of the National Academy of Sciences of the United States of America, 109 (2012) 13243-13247.

[76] K. Beck, B. Brodsky, Supercoiled protein motifs: The collagen triple-helix and the alphahelical coiled coil, Journal of Structural Biology, 122 (1998) 17-29.

[77] G. Melacini, A. Bonvin, M. Goodman, R. Boelens, R. Kaptein, Hydration dynamics of the collagen triple helix by NMR, Journal of Molecular Biology, 300 (2000) 1041-1048.

[78] D. Motooka, K. Kawahara, S. Nakamura, M. Doi, Y. Nishi, Y. Nishiuchi, Y.K. Kang, T. Nakazawa, S. Uchiyama, T. Yoshida, T. Ohkubo, Y. Kobayashi, The triple helical structure and stability of collagen model peptide with 4(s)-hydroxyprolyl-pro-gly units, Biopolymers, 98 (2012) 111-121.

[79] K.E. Kadler, D.F. Holmes, J.A. Trotter, J.A. Chapman, Collagen fibril formation, The Biochemical Journal, 316 (Pt 1) (1996) 1-11.

[80] T.J. Wess, A.P. Hammersley, L. Wess, A. Miller, Molecular packing of type I collagen in tendon, Journal of Molecular Biology, 275 (1998) 255-267.

[81] M. Fang, E.L. Goldstein, A.S. Turner, C.M. Les, B.G. Orr, G.J. Fisher, K.B. Welch, E.D. Rothman, M.M.B. Holl, Type I collagen D-spacing in fibril bundles of dermis, tendon, and bone: bridging between nano- and micro-level tissue hierarchy, ACS Nano, 6 (2012) 9503-9514.

[82] M. Kjaer, H. Langberg, K. Heinemeier, M.L. Bayer, M. Hansen, L. Holm, S. Doessing, M. Kongsgaard, M.R. Krogsgaard, S.P. Magnusson, From mechanical loading to collagen synthesis,

structural changes and function in human tendon, Scandinavian Journal of Medicine & Science in Sports, 19 (2009) 500-510.

[83] R.J. Wenstrup, S.M. Smith, J.B. Florer, G.Y. Zhang, D.P. Beason, R.E. Seegmiller, L.J. Soslowsky, D.E. Birk, Regulation of collagen fibril nucleation and initial fibril assembly involves coordinate interactions with collagens V and XI in developing tendon, Journal of Biological Chemistry, 286 (2011) 20455-20465.

[84] C. Kielty, I. Hopkinson, M. Grant, Collagen: The collagen family: Structure, assembly, and organization in the extracellular matrix, 1993.

[85] M. Tsuzaki, M. Yamauchi, A.J. Banes, Tenon collagens - Extracellular-matrix composition in shear-stress and tensile components of flexor tendons, Connective Tissue Research, 29 (1993) 141-152.

[86] R.J. Hill, E. Harper, Quantitation of type-I and type-III collagens in human-tissue samples and cell-culture by cyanogen-bromide peptide ananlysis, Analytical Biochemistry, 141 (1984) 83-93.

[87] P.K. Mays, J.E. Bishop, G.J. Laurent, Age-related-changes in the proportion of type-I and type-III collagen, Mechanisms of Ageing and Development, 45 (1988) 203-212.

[88] D.E. Birk, J.M. Fitch, J.P. Babiarz, K.J. Doane, T.F. Linsenmayer, Collagen fibrillogenesis in vitro: interaction of types I and V collagen regulates fibril diameter, Journal of Cell Science, 95 (Pt 4) (1990) 649-657.

[89] D.E. Birk, R. Mayne, Localization of collagen types I, III and V during tendon development. Changes in collagen types I and III are correlated with changes in fibril diameter, European Journal of Cell Biology, 72 (1997) 352-361.

[90] K. Arai, Y. Kasashima, A. Kobayashi, A. Kuwano, T. Yoshihara, TGF-beta alters collagen XII and XIV mRNA levels in cultured equine tenocytes, Matrix Biology, 21 (2002) 243-250.

[91] M. Posthumus, A.V. September, D. O'Cuinneagain, W. van der Merwe, M.P. Schwellnus, M. Collins, The association between the COL12A1 gene and anterior cruciate ligament ruptures, Br J Sports Med, 44 (2010) 1160-1165.

[92] A.V. September, M. Posthumus, L. van der Merwe, M. Schwellnus, T.D. Noakes, M. Collins, The COL12A1 and COL14A1 genes and Achilles tendon injuries, Int J Sports Med, 29 (2008) 257-263.

[93] C.M. Kielty, S. Stephan, M.J. Sherratt, M. Williamson, C.A. Shuttleworth, Applying elastic fibre biology in vascular tissue engineering, Philosophical Transactions of the Royal Society B-Biological Sciences, 362 (2007) 1293-1312.

[94] A. Bailey, The chemistry of natural enzyme-induced cross-links of protiens, Amino Acids (Vienna), 1 (1991) 293-306.

[95] S.M. Mithieux, A.S. Weiss, Elastin, in: Parry, D.A.D., Squire, J.M. (Eds.) Fibrous Proteins: Coiled-coils, Collagen and Elastomers2005, pp. 437-461.

[96] D.L. Butler, E.S. Grood, F.R. Noyes, R.F. Zernicke, Biomechanics of ligaments and tendons, Exercise and Sport Sciences Reviews, 6 (1978) 125-181.

[97] H.L. Birch, S. Worboys, S. Eissa, B. Jackson, S. Strassburg, P.D. Clegg, Matrix metabolism rate differs in functionally distinct tendons, Matrix Biology, 27 (2008) 182-189.

[98] K.A. Derwin, L.J. Soslowsky, J.H. Kimura, A.H. Plaas, Proteoglycans and glycosaminoglycan fine structure in the mouse tail tendon fascicle, Journal of Orthopaedic Research, 19 (2001) 269-277.

[99] C. Ruhland, E. Schonherr, H. Robenek, U. Hansen, R.V. Iozzo, P. Bruckner, D.G. Seidler, The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis, The FEBS journal, 274 (2007) 4246–4255.

[100] J.H. Yoon, J. Halper, Tendon proteoglycans: Biochemistry and function, Journal of Musculoskeletal & Neuronal Interactions, 5 (2005) 22-34.

[101] T. Samiric, J. Parkinson, M.Z. Ilic, J. Cook, J.A. Feller, C.J. Handley, Changes in the composition of the extracellular matrix in patellar tendinopathy, Matrix Biology, 28 (2009) 230-236.

[102] C.T. Thorpe, H.L. Birch, P.D. Clegg, H.R. Screen, The role of the non-collagenous matrix in tendon function, International Journal of Experimental Pathology, 94 (2013) 248-259.

[103] M. Attia, A. Scott, A. Duchesnay, G. Carpentier, L.J. Soslowsky, M.B. Huynh, T.H. Van Kuppevelt, C. Gossard, J. Courty, M.-C. Tassoni, I. Martelly, Alterations of overused supraspinatus tendon: A possible role of glycosaminoglycans and HARP/pleiotrophin in early tendon pathology, Journal of Orthopaedic Research, 30 (2012) 61-71.

[104] M.C. Berenson, F.T. Blevins, A.H.K. Plaas, K.G. Vogel, Proteoglycans of human rotator cuff tendons, Journal of Orthopaedic Research, 14 (1996) 518-525.

[105] K. Stuart, A. Panitch, Influence of chondroitin sulfate on collagen gel structure and mechanical properties at physiologically relevant levels, Biopolymers, 89 (2008) 841-851.

[106] G. Riley, The pathogenesis of tendinopathy. A molecular perspective, Rheumatology, 43 (2004) 131-142.

[107] P. Sharma, N. Maffulli, Tendon injury and tendinopathy: Healing and repair, The Journal of Bone and Joint Surgery-American Volume, 87 (2005) 187-202.

[108] P.K. Beredjiklian, Biological aspects of flexor tendon laceration and repair, The Journal of Bone and Joint Surgery, 85 (2003) 539-550.

[109] Z. Yin, X. Chen, J.-l. Chen, H.-W. Ouyang, Stem cells for tendon tissue engineering and regeneration, Expert Opinion on Biological Therapy, 10 (2010) 689-700.

[110] C.-F. Liu, L. Aschbacher-Smith, N.J. Barthelery, N. Dyment, D. Butler, C. Wylie, What we should know before using tissue engineering techniques to repair injured tendons: A developmental biology perspective, Tissue Engineering Part B: Reviews, 17 (2011) 165-176.

[111] R. Bullough, T. Finnigan, A. Kay, N. Maffulli, N.R. Forsyth, Tendon repair through stem cell intervention: Cellular and molecular approaches, Disability and Rehabilitation, 30 (2008) 1746-1751.

[112] P.P. Lui, S.W. Ng, Cell therapy for the treatment of tendinopathy -- A systematic review on the pre-clinical and clinical evidence, Seminars in Arthritis and Rheumatism, 42 (2013) 651-666.

[113] S.A. Fenwick, B.L. Hazleman, G.P. Riley, The vasculature and its role in the damaged and healing tendon, Arthritis Research, 4 (2002) 252-260.

[114] M.A. Platt, Tendon repair and healing, Clinics in Podiatric Medicine and Surgery, 22 (2005) 553-560.

[115] S. Liu, R. Yang, R. al-Shaikh, J. Lane, Collagen in tendon, ligament, and bone healing. A current review, Clin Orthop Relat Res, 318 (1995) 265-278.

[116] A.M.A. Oryan, A long term study on the role of exogenous human recombinant basic fibroblast growth factor on the superficial digital flexor tendon healing in rabbits, Journal of Musculoskeletal and Neuronal Interactions, 11 (2011) 185-195.

[117] A.A. Dunkman, M.R. Buckley, M.J. Mienaltowski, S.M. Adams, S.J. Thomas, L. Satchell, A. Kumar, L. Pathmanathan, D.P. Beason, R.V. Iozzo, D.E. Birk, L.J. Soslowsky, The tendon injury response is influenced by decorin and biglycan, Annals of Biomedical Engineering, 42 (2014) 619-630.

[118] S. Hasslund, J.A. Jacobson, T. Dadali, P. Basile, M. Ulrich-Vinther, K. Soballe, E.M. Schwarz, R.J. O'Keefe, D.J. Mitten, H.A. Awad, Adhesions in a murine flexor tendon graft model: Autograft versus allograft reconstruction, Journal of Orthopaedic Research, 26 (2008) 824-833.

[119] E. Frykman, S. Jacobsson, B. Widenfalk, Fibrin sealant in prevention of flexor tendon adhesions: An experimental study in the rabbit, The Journal of Hand Surgery, 18 (1993) 68-75.

[120] J.B. Tang, Clinical outcomes associated with flexor tendon repair, Hand Clin, 21 (2005) 199-210.

[121] J.L. Drury, D.J. Mooney, Hydrogels for tissue engineering: Scaffold design variables and applications, Biomaterials, 24 (2003) 4337-4351.

[122] E.S. Place, N.D. Evans, M.M. Stevens, Complexity in biomaterials for tissue engineering, Nature Materials, 8 (2009) 457-470.

[123] T. de Wit, D. de Putter, W.M.W. Tra, H.A. Rakhorst, G. van Osch, S.E.R. Hovius, J.W. van Neck, Auto-crosslinked hyaluronic acid gel accelerates healing of rabbit flexor tendons in vivo, Journal of Orthopaedic Research, 27 (2009) 408-415.

[124] W. Friess, Collagen - biomaterial for drug delivery, European Journal of Pharmaceutics and Biopharmaceutics, 45 (1998) 113-136.

[125] C.H. Lee, A. Singla, Y. Lee, Biomedical applications of collagen, International Journal of Pharmaceutics, 221 (2001) 1-22.

[126] J.D. Berglund, M.M. Mohseni, R.M. Nerem, A. Sambanis, A biological hybrid model for collagen-based tissue engineered vascular constructs, Biomaterials, 24 (2003) 1241-1254.

[127] D. Zeugolis, M. Raghunath, Collagen: Materials analysis and implant uses, in: Ducheyne, P., Healy, K., Hutmacher, D., Grainger, D., Kirkpatrick, C. (Eds.) Comprehensive Biomaterials, Elsevier2011, pp. 261-278.

[128] N.C. Hunt, L.M. Grover, Cell encapsulation using biopolymer gels for regenerative medicine, Biotechnology Letters, 32 (2010) 733-742.

[129] A. Pacini, C. Gardi, F. Corradeschi, A. Viti, C. Belli, P. Calzoni, G. Lungarella, In vivo stimulation of lung collagen synthesis by collagen derived peptides, Research Communications in Chemical Pathology and Pharmacology, 68 (1990) 89-101.

[130] A. Del Buono, F. Oliva, L. Osti, N. Maffulli, Metalloproteases and tendinopathy, Muscles Ligaments Tendons Journal, 3 (2013) 51-57.

[131] H. Ueda, N. Meguri, J. Minaguchi, T. Watanabe, A. Nagayasu, Y. Hosaka, P. Tangkawattana, Y. Kokai, K. Takehana, Effect of collagen oligopeptide injection on rabbit tenositis, The Journal of Veterinary Medical Science, 70 (2008) 1295-1300.

[132] L.S. Nair, C.T. Laurencin, Biodegradable polymers as biomaterials, Progress in Polymer Science, 32 (2007) 762-798.

[133] T. Ahmed, E. Dare, M. Hincke, Fibrin: A versatile scaffold for tissue engineering applications, Tissue Engineering Part B: Reviews, 14 (2008) 199-215.

[134] C. Wong, E. Inman, R. Spaethe, S. Helgerson, Fibrin-based biomaterials to deliver human growth factors, Thrombosis and Haemostasis, 89 (2003) 573-582.

[135] S. Thomopoulos, L.J. Soslowsky, C.L. Flanagan, S. Tun, C.C. Keefer, J. Mastaw, J.E. Carpenter, The effect of fibrin clot on healing rat supraspinatus tendon defects, Journal of Shoulder and Elbow Surgery, 11 (2002) 239-247.

[136] D.A. Lusardi, J.E. Cain, Jr., The effect of fibrin sealant on the strength of tendon repair of full thickness tendon lacerations in the rabbit Achilles tendon, The Journal of Foot and Ankle Surgery, 33 (1994) 443-447.

[137] H. Thermann, O. Frerichs, A. Biewener, C. Krettek, Healing of the Achilles tendon: An experimental study, Foot and Ankle International, 22 (2001) 478-483.

[138] C. Redaelli, U. Niederhäuser, T. Carrel, U. Meier, O. Trentz, Rupture of the Achilles tendon -Fibrin gluing or suture?, Chirurg, 63 (1992) 572-576.

[139] B. Hohendorff, W. Siepen, L. Spiering, L. Staub, T. Schmuck, A. Boss, Long-term results after operatively treated Achilles tendon rupture: Fibrin glue versus suture, The Journal of Foot and Ankle Surgery, 47 (2008) 392-399.

[140] B.M. Andres, G.A. Murrell, Treatment of tendinopathy: What works, what does not, and what is on the horizon, Clin Orthop Relat Res, 466 (2008) 1539-1554.

[141] G. Riley, Tendinopathy - From basic science to treatment, Nature Clinical Practice Rheumatology, 4 (2008) 82-89.

[142] P.T. Dawes, D.P. Symmons, Short-term effects of antirheumatic drugs, Bailliere's Clinical Rheumatology, 6 (1992) 117-140.

[143] G.P. Riley, M. Cox, R.L. Harrall, S. Clements, B.L. Hazleman, Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro, Journal of Hand Surgery (Edinburgh, Scotland), 26 (2001) 224-228.

[144] J.R. Andrews, Diagnosis and treatment of chronic painful shoulder: Review of nonsurgical interventions, Arthroscopy, 21 (2005) 333-347.

[145] T.A. Blaine, Diagnosis, pathology, and nonsurgical treatment of painful shoulder, Arthroscopy, 22 (2006) 117-118.

[146] N. Scutt, C.G. Rolf, A. Scutt, Glucocorticoids inhibit tenocyte proliferation and tendon progenitor cell recruitment, Journal of Orthopaedic Research, 24 (2006) 173-182.

[147] J.A. Paoloni, G.A.C. Murrell, Three-year followup study of topical glyceryl trinitrate treatment of chronic noninsertional Achilles tendinopathy, Foot & Ankle International, 28 (2007) 1064-1068.

[148] A.R. Bokhari, G.A. Murrell, The role of nitric oxide in tendon healing, Journal of Shoulder and Elbow Surgery, 21 (2012) 238-244.

[149] T.P.C. Kane, M. Ismail, J.D.F. Calder, Topical glyceryl trinitrate and noninsertional Achilles tendinopathy - A clinical and cellular investigation, Am J Sports Med, 36 (2008) 1160-1163.

[150] J.A. Paoloni, R.C. Appleyard, J. Nelson, G.A.C. Murrell, Topical nitric oxide application in the treatment of chronic extensor tendinosis at the elbow - A randomized, double-blinded, placebocontrolled clinical trial, Am J Sports Med, 31 (2003) 915-920.

[151] S.P. Nichols, W.L. Storm, A. Koh, M.H. Schoenfisch, Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues, Advanced Drug Delivery Reviews, 64 (2012) 1177-1188.

[152] E.M. Gaughan, A.J. Nixon, L.P. Krook, A.E. Yeager, K.A. Mann, H. Mohammed, D.L. Bartel, Effects of sodium hyaluronate on tendon healing and adhesion formation in horses, American Journal of Veterinary Research, 52 (1991) 764-773.

[153] Y. Shibata, K. Midorikawa, G. Emoto, M. Naito, Clinical evaluation of sodium hyaluronate for the treatment of patients with rotator cuff tear, Journal of Shoulder and Elbow Surgery, 10 (2001) 209-216.

[154] T. Muneta, H. Koga, Y.J. Ju, T. Mochizuki, I. Sekiya, Hyaluronan injection therapy for athletic patients with patellar tendinopathy, Journal of Orthopaedic Science, 17 (2012) 425-431.

[155] G.Y. Ozgenel, A. Etoz, Effects of repetitive injections of hyaluronic acid on peritendinous adhesions after flexor tendon repair: A preliminary randomized, placebo-controlled clinical trial, Ulus Travma Acil Cerrahi Derg, 18 (2012) 11-17.

[156] T. Moro-oka, H. Miura, T. Mawatari, T. Kawano, Y. Nakanishi, H. Higaki, Y. Iwamoto, Mixture of hyaluronic acid and phospholipid prevents adhesion formation on the injured flexor tendon in rabbits, Journal of Orthopaedic Research, 18 (2000) 835-840.

[157] M. Paavola, P. Kannus, T.A. Jarvinen, T.L. Jarvinen, L. Jozsa, M. Jarvinen, Treatment of tendon disorders. Is there a role for corticosteroid injection?, Foot and Ankle Clinics, 7 (2002) 501-513.

[158] B.T. Fitzgerald, E.P. Hofmeister, R.A. Fan, M.A. Thompson, Delayed flexor digitorum superficialis and profundus ruptures in a trigger finger after a steroid injection: A case report, The Journal of Hand Surgery, 30 (2005) 479-482.

[159] C.Y. Woon, E.S. Phoon, J.Y. Lee, S.W. Ng, L.C. Teoh, Hazards of steroid injection: suppurative extensor tendon rupture, Indian Journal of Plastic Surgery, 43 (2010) 97-100.

[160] B.K. Coombes, L. Bisset, B. Vicenzino, Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: A systematic review of randomised controlled trials, Lancet, 376 (2010) 1751-1767.

[161] W.J. King, P.H. Krebsbach, Growth factor delivery: How surface interactions modulate release in vitro and in vivo, Advanced Drug Delivery Reviews, 64 (2012) 1239-1256.

[162] N. Bachl, W. Derman, L. Engebretsen, G. Goldspink, M. Kinzlbauer, H. Tschan, P. Volpi, D. Venter, B. Wessner, Therapeutic use of growth factors in the musculoskeletal system in sports-related injuries, Journal of Sports Medicine and Physical Fitness, 49 (2009) 346-357.

[163] L.V. Gulotta, S.A. Rodeo, Growth factors for rotator cuff repair, Clin Sports Med, 28 (2009)13-23.

[164] R.J. de Vos, P.L.J. van Veldhoven, M.H. Moen, A. Weir, J.L. Tol, N. Maffulli, Autologous growth factor injections in chronic tendinopathy: A systematic review, British Medical Bulletin, 95 (2010) 63-77.

[165] S. Thomopoulos, F.L. Harwood, M.J. Silva, D. Amiel, R.H. Gelberman, Effect of several growth factors on canine flexor tendon fibroblast proliferation and collagen synthesis in vitro, The Journal of Hand Surgery, 30 (2005) 441-447.

[166] M.A. Costa, C. Wu, B.V. Pham, A.K. Chong, H.M. Pham, J. Chang, Tissue engineering of flexor tendons: Optimization of tenocyte proliferation using growth factor supplementation, Tissue Engineering, 12 (2006) 1937-1943.

[167] A.L. Ponte, E. Marais, N. Gallay, A. Langonne, B. Delorme, O. Herault, P. Charbord, J. Domenech, The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities, Stem Cells, 25 (2007) 1737-1745.

[168] R. James, G. Kesturu, G. Balian, A.B. Chhabra, Tendon: Biology, biomechanics, repair, growth factors, and evolving treatment options, Journal of Hand Surgery-American Volume, 33A (2008) 102-112.

[169] J.R. Chen, L. Yang, L. Guo, X.J. Duan, Sodium hyaluronate as a drug-release system for VEGF 165 improves graft revascularization in anterior cruciate ligament reconstruction in a rabbit model, Experimental and Therapeutic Medicine, 4 (2012) 430-434.

[170] S. Thomopoulos, R. Das, M.J. Silva, S. Sakiyama-Elbert, F.L. Harwood, E. Zampiakis, H.M. Kim, D. Amiel, R.H. Gelberman, Enhanced flexor tendon healing through controlled delivery of PDGF-BB, Journal of Orthopeadic Research, 27 (2009) 1209-1215.

[171] S. Sahoo, S.L. Toh, J.C. Goh, A bFGF-releasing silk/PLGA-based biohybrid scaffold for ligament/tendon tissue engineering using mesenchymal progenitor cells, Biomaterials, 31 (2010) 2990-2998.

[172] S. Violini, P. Ramelli, L.F. Pisani, C. Gorni, P. Mariani, Horse bone marrow mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic differentiation by in vitro exposure to BMP-12, BMC Cell Biology, 10 (2009) 29.

[173] J.Y. Lee, Z. Zhou, P.J. Taub, M. Ramcharan, Y. Li, T. Akinbiyi, E.R. Maharam, D.J. Leong, D.M. Laudier, T. Ruike, P.J. Torina, M. Zaidi, R.J. Majeska, M.B. Schaffler, E.L. Flatow, H.B. Sun, BMP-12 treatment of adult mesenchymal stem cells in vitro augments tendon-like tissue formation and defect repair in vivo, PLoS One, 6 (2011) e17531.

[174] J. Lou, Y. Tu, M. Burns, M.J. Silva, P. Manske, BMP-12 gene transfer augmentation of lacerated tendon repair, Journal of Orthopeadic Research, 19 (2001) 1199-1202.

[175] S.P. Berasi, U. Varadarajan, J. Archambault, M. Cain, T.A. Souza, A. Abouzeid, J. Li, C.T. Brown, A.J. Dorner, H.J. Seeherman, S.A. Jelinsky, Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent of receptor binding affinities, Growth Factors, 29 (2011) 128-139.

[176] O.A. Branford, B.R. Klass, A.O. Grobbelaar, K.J. Rolfe, The growth factors involved in flexor tendon repair and adhesion formation, Journal of Hand Surgery (European Volume), 39 (2014) 60-70.

[177] M.J. Guerquin, B. Charvet, G. Nourissat, E. Havis, O. Ronsin, M.A. Bonnin, M. Ruggiu, I. Olivera-Martinez, N. Robert, Y.H. Lu, K.E. Kadler, T. Baumberger, L. Doursounian, F. Berenbaum, D. Duprez, Transcription factor EGR1 directs tendon differentiation and promotes tendon repair, Journal of Clinical Investigation, 123 (2013) 3564-3576.

[178] B.A. Pryce, S.S. Watson, N.D. Murchison, J.A. Staverosky, N. Dunker, R. Schweitzer, Recruitment and maintenance of tendon progenitors by TGFbeta signaling are essential for tendon formation, Development, 136 (2009) 1351-1361.

[179] M. Hansen, A. Boesen, L. Holm, A. Flyvbjerg, H. Langberg, M. Kjaer, Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans, Scandinavian Journal of Medicine & Science in Sports, 23 (2013) 614-619.

[180] N.M. Wolfman, G. Hattersley, K. Cox, A.J. Celeste, R. Nelson, N. Yamaji, J.L. Dube, E. DiBlasio-Smith, J. Nove, J.J. Song, J.M. Wozney, V. Rosen, Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family, The Journal of Clinical Investigation, 100 (1997) 321-330.

[181] T. Molloy, Y. Wang, G. Murrell, The roles of growth factors in tendon and ligament healing, Sports Med, 33 (2003) 381-394.

[182] T.E. Foster, B.L. Puskas, B.R. Mandelbaum, M.B. Gerhardt, S.A. Rodeo, Platelet-rich plasma from basic science to clinical applications, Am J Sports Med, 37 (2009) 2259-2272.

[183] D.W. Taylor, M. Petrera, M. Hendry, J.S. Theodoropoulos, A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries, Clinical Journal of Sport Medicine, 21 (2011) 344-352.

[184] I. Andia, M. Sanchez, N. Maffulli, Platelet rich plasma therapies for sports muscle injuries: Any evidence behind clinical practice?, Expert Opinion on Biological Therapy, 11 (2011) 509-518.

[185] L.V. Schnabel, H.O. Mohammed, B.J. Miller, W.G. McDermott, M.S. Jacobson, K.S. Santangelo, L.A. Fortier, Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons, Journal of Orthopaedic Research, 25 (2007) 230-240.

[186] G. Bosch, H.T.A. van Schie, M.W. de Groot, J.A. Cadby, C.H.A. van de Lest, A. Barneveld, P.R. van Weeren, Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo-controlled experimental study, Journal of Orthopaedic Research, 28 (2010) 211-217.

[187] G. Bosch, M. Moleman, A. Barneveld, P.R. van Weeren, H.T.M. van Schie, The effect of platelet-rich plasma on the neovascularization of surgically created equine superficial digital flexor tendon lesions, Scandinavian Journal of Medicine & Science in Sports, 21 (2011) 554-561.

[188] R.L. Fontenot, C.A. Sink, S.R. Werre, N.M. Weinstein, L.A. Dahlgren, Simple tube centrifugation for processing platelet-rich plasma in the horse, Canadian Veterinary Journal-Revue Veterinaire Canadienne, 53 (2012) 1266-1272.

[189] S. Sampson, M. Gerhardt, B. Mandelbaum, Platelet rich plasma injection grafts for musculoskeletal injuries: A review, Current Reviews in Musculoskeletal Medicine, 1 (2008) 165-174.

[190] I. Andia, M. Sanchez, N. Maffulli, Tendon healing and platelet-rich plasma therapies, Expert Opinion on Biological Therapy, 10 (2010) 1415-1426.

[191] G. Filardo, E. Kon, B. Di Matteo, P. Pelotti, A. Di Martino, M. Marcacci, Platelet-rich plasma for the treatment of patellar tendinopathy: Clinical and imaging findings at medium-term follow-up, International Orthopaedics, 37 (2013) 1583-1589.

[192] J.F. Kaux, J.L. Croisier, O. Bruyere, C. Rodriguez, C. Daniel, B. Godon, P. Simoni, V. Alvarez, G. Brabant, S. Lapraille, V. Lonneux, D. Noel, J. Collette, C.L. Goff, A. Gothot, J.M. Crielaard, Platelet-rich plasma (PRP) to treat chronic upper patellar tendinopathies, Br J Sports Med, 47 (2013) e3.

[193] S.W. Cheatham, M.J. Kolber, P.A. Salamh, W.J. Hanney, Rehabilitation of a partially torn distal triceps tendon after platelet rich plasma injection: A case report, International Journal of Sports Physical Therapy, 8 (2013) 290-299.

[194] M. Vetrano, A. Castorina, M.C. Vulpiani, R. Baldini, A. Pavan, A. Ferretti, Platelet-rich plasma versus focused shock waves in the treatment of jumper's knee in athletes, Am J Sports Med, 41 (2013) 795-803.

[195] R.A. Magnussen, D.C. Flanigan, A.D. Pedroza, K.A. Heinlein, C.C. Kaeding, Platelet rich plasma use in allograft ACL reconstructions: Two-year clinical results of a MOON cohort study, Knee, 20 (2013) 277-280.

[196] R.J. de Vos, A. Weir, H.T.M. van Schie, S.M.A. Bierma-Zeinstra, J.A.N. Verhaar, H. Weinans, J.L. Tol, Platelet-rich plasma injection for chronic Achilles tendinopathy a randomized controlled trial, Jama-Journal of the American Medical Association, 303 (2010) 144-149.

[197] T. Schepull, J. Kvist, H. Norrman, M. Trinks, G. Berlin, P. Aspenberg, Autologous platelets have no effect on the healing of human Achilles tendon ruptures a randomized single-blind study, Am J Sports Med, 39 (2011) 38-47.

[198] K.F. Bowman, B. Muller, K. Middleton, C. Fink, C.D. Harner, F.H. Fu, Progression of patellar tendinitis following treatment with platelet-rich plasma: Case reports, Knee Surgery, Sports Traumatology, Arthroscopy, 21 (2013) 2035-2039.

[199] R. Landesberg, M. Moses, M. Karpatkin, Risks of using platelet rich plasma gel, Journal of Oral and Maxillofacial Surgery, 56 (1998) 1116-1117.

[200] S.M. O'Connell, T. Impeduglia, K. Hessler, X.J. Wang, R.J. Carroll, H. Dardik, Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers, Wound Repair Regen, 16 (2008) 749-756.

[201] D. Fufa, B. Shealy, M. Jacobson, S. Kevy, M.M. Murray, Activation of platelet-rich plasma using soluble type I collagen, J Oral Maxillofac Surg, 66 (2008) 684-690.

[202] S.G. Boswell, B.J. Cole, E.A. Sundman, V. Karas, L.A. Fortier, Platelet-rich plasma: A milieu of bioactive factors, Arthroscopy, 28 (2012) 429-439.

[203] A.J. Nixon, A.E. Watts, L.V. Schnabel, Cell- and gene-based approaches to tendon regeneration, Journal of Shoulder and Elbow Surgery, 21 (2012) 278-294.

[204] A. Pascher, A.F. Steinert, G.D. Palmer, O. Betz, J.N. Gouze, E. Gouze, C. Pilapil, S.C. Ghivizzani, C.H. Evans, M.M. Murray, Enhanced repair of the anterior cruciate ligament by in situ gene transfer: Evaluation in an in vitro model, Molecular Therapy, 10 (2004) 327-336.

[205] M. Majewski, R.M. Porter, O.B. Betz, V.M. Betz, H. Clahsen, R. Fluckiger, C.H. Evans, Improvement of tendon repair using muscle grafts transduced with TGF-beta cDNA, European Cells & Materials, 23 (2012) 94-102.

[206] A. Delalande, A. Bouakaz, G. Renault, F. Tabareau, S. Kotopoulis, P. Midoux, B. Arbeille, R. Uzbekov, S. Chakravarti, M. Postema, C. Pichon, Ultrasound and microbubble-assisted gene delivery in Achilles tendons: Long lasting gene expression and restoration of fibromodulin KO phenotype, Journal of Controlled Release, 156 (2011) 223-230.

[207] Y.L. Zhou, L.Z. Zhang, W.X. Zhao, Y.F. Wu, C.L. Zhu, Y.M. Yang, Nanoparticle-mediated delivery of TGF-beta 1 miRNA plasmid for preventing flexor tendon adhesion formation, Biomaterials, 34 (2013) 8269-8278.

[208] I.M. Verma, N. Somia, Gene therapy -- Promises, problems and prospects, Nature, 389 (1997)239-242.

[209] M.A. Kay, J.C. Glorioso, L. Naldini, Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics, Nature Medicine, 7 (2001) 33-40.

[210] K. Spanoudes, D. Gaspar, A. Pandit, D. Zeugolis, The biophysical, biochemical, and biological toolbox for tenogenic phenotype maintenance in vitro, Trends in Biotechnology, 32 (2014) 474-482.

[211] F. Belema-Bedada, S. Uchida, A. Martire, S. Kostin, T. Braun, Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2, Cell Stem Cell, 2 (2008) 566-575.

[212] S. Meirelles Lda, A.M. Fontes, D.T. Covas, A.I. Caplan, Mechanisms involved in the therapeutic properties of mesenchymal stem cells, Cytokine & Growth Factor Reviews, 20 (2009) 419-427.

[213] R.I. Sharma, J.G. Snedeker, Paracrine interactions between mesenchymal stem cells affect substrate driven differentiation toward tendon and bone phenotypes, PLoS One, 7 (2012) e31504.

[214] R.K. Smith, Mesenchymal stem cell therapy for equine tendinopathy, Disability and Rehabilitation, 30 (2008) 1752-1758.

[215] R.K.W. Smith, M. Korda, G.W. Blunn, A.E. Goodship, Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment, Equine Veterinary Journal, 35 (2003) 99-102.

[216] E.E. Godwin, N.J. Young, J. Dudhia, I.C. Beamish, R.K.W. Smith, Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon, Equine Veterinary Journal, 44 (2012) 25-32.

[217] S. Pacini, S. Spinabella, L. Trombi, R. Fazzi, S. Galimberti, F. Dini, F. Carlucci, M. Petrini, Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses, Tissue Engineering, 13 (2007) 2949-2955.

[218] N. Matsuda, T. Shimizu, M. Yamato, T. Okano, Tissue engineering based on cell sheet technology, Advanced Materials, 19 (2007) 3089-3099.

[219] N. Okamoto, T. Kushida, K. Oe, M. Umeda, S. Ikehara, H. Iida, Treating Achilles tendon rupture in rats with bone-marrow-cell transplantation therapy, The Journal of Bone and Joint Surgery-American Volume, 92 (2010) 2776-2784.

[220] J. van Ramshorst, S. Rodrigo, M. Schalij, S. Beeres, J. Bax, D. Atsma, Bone marrow cell injection for chronic myocardial ischemia: The past and the future, Journal of Cardiovascular Translational Research, 4 (2011) 182-191.

[221] F. Cellesi, Thermoresponsive hydrogels for cellular delivery, Therapeutic Delivery, 3 (2012) 1395-1407.

[222] K.Y. Lee, D.J. Mooney, Hydrogels for tissue engineering, Chemical Reviews, 101 (2001) 1869-1880.

[223] Z. Yang, G. Liang, M. Ma, A. Abbah, W. Lu, B. Xu, D-glucosamine-based supramolecular hydrogels to improve wound healing, Chemical Communications (Cambridge, England), 8 (2007) 843-845.

[224] S.A. Abbah, W.W. Lu, S.L. Peng, D.M. Aladin, Z.Y. Li, W.K. Tam, K.M. Cheung, K.D. Luk, G.Q. Zhou, Extracellular matrix stability of primary mammalian chondrocytes and intervertebral disc cells cultured in alginate-based microbead hydrogels, Cell Transplant, 17 (2008) 1181-1192.

[225] O.Z. Fisher, A. Khademhosseini, R. Langer, N.A. Peppas, Bioinspired materials for controlling stem cell fate, Accounts of Chemical Research, 43 (2009) 419-428.

[226] E.C. Collin, S. Grad, D.I. Zeugolis, C.S. Vinatier, J.R. Clouet, J.J. Guicheux, P. Weiss, M. Alini, A.S. Pandit, An injectable vehicle for nucleus pulposus cell-based therapy, Biomaterials, 32 (2011) 2862-2870.

[227] J.A. Burdick, G.D. Prestwich, Hyaluronic acid hydrogels for biomedical applications, Advanced Materials, 23 (2011) H41-H56.

[228] B.A. Aguado, W. Mulyasasmita, J. Su, K.J. Lampe, S.C. Heilshorn, Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers, Tissue Engineering Part A, 18 (2012) 806-815.

[229] R. Rizzi, C. Bearzi, A. Mauretti, S. Bernardini, S. Cannata, C. Gargioli, Tissue engineering for skeletal muscle regeneration, Muscles Ligaments Tendons Journal, 2 (2012) 230-234.

[230] P.K. Vemula, N. Wiradharma, J.A. Ankrum, O.R. Miranda, G. John, J.M. Karp, Prodrugs as self-assembled hydrogels: A new paradigm for biomaterials, Current Opinion in Biotechnology, 24 (2013) 1174-1182.

[231] F. Munarin, P. Petrini, S. Bozzini, M.C. Tanzi, New perspectives in cell delivery systems for tissue regeneration: Natural-derived injectable hydrogels, Journal of Applied Biomaterials & Functional Materials, 10 (2012) 67-81.

[232] H.A. Awad, G.P. Boivin, M.R. Dressler, F.N. Smith, R.G. Young, D.L. Butler, Repair of patellar tendon injuries using a cell-collagen composite, Journal of Orthopeadic Research, 21 (2003) 420-431.

[233] L. Lacitignola, F. Staffieri, G. Rossi, E. Francioso, A. Crovace, Survival of bone marrow mesenchymal stem cells labelled with red fluorescent protein in an ovine model of collagenaseinduced tendinitis, Veterinary and Comparative Orthopaedics and Traumatology, 27 (2014) 204-209.

[234] S. Hankemeier, M. van Griensven, M. Ezechieli, T. Barkhausen, M. Austin, M. Jagodzinski, R. Meller, U. Bosch, C. Krettek, J. Zeichen, Tissue engineering of tendons and ligaments by human bone marrow stromal cells in a liquid fibrin matrix in immunodeficient rats: Results of a histologic study, Archives of Orthopaedic and Trauma Surgery, 127 (2007) 815-821.

[235] S. Hankemeier, C. Hurschler, J. Zeichen, M. van Griensven, B. Miller, R. Meller, M. Ezechieli, C. Krettek, M. Jagodzinski, Bone marrow stromal cells in a liquid fibrin matrix improve the healing process of patellar tendon window defects, Tissue Engineering Part A, 15 (2009) 1019-1030.

[236] A.S. Hoffman, Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation, Advanced Drug Delivery Reviews, 65 (2013) 10-16.

[237] A. Chan, R.P. Orme, R.A. Fricker, P. Roach, Remote and local control of stimuli responsive materials for therapeutic applications, Advanced Drug Delivery Reviews, 65 (2013) 497-514.

[238] H.B. Sun, N. Andarawis-Puri, Y. Li, D.T. Fung, J.Y. Lee, V.M. Wang, J. Basta-Pljakic, D.J. Leong, J.B. Sereysky, S.J. Ros, R.A. Klug, J. Braman, M.B. Schaffler, K.J. Jepsen, E.L. Flatow, Cycle-dependent matrix remodeling gene expression response in fatigue-loaded rat patellar tendons, Journal of Orthopeadic Research, 28 (2010) 1380-1386.

[239] J. Patterson, J.A. Hubbell, Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2, Biomaterials, 31 (2010) 7836-7845.

[240] J.A. Gustafson, R.A. Price, J. Frandsen, C.R. Henak, J. Cappello, H. Ghandehari, Synthesis and characterization of a matrix-metalloproteinase responsive silk-elastinlike protein polymer, Biomacromolecules, 14 (2013) 618-625.

[241] L. Xiao, Z. Tong, Y. Chen, D.J. Pochan, C.R. Sabanayagam, X. Jia, Hyaluronic acid-based hydrogels containing covalently integrated drug depots: Implication for controlling inflammation in mechanically stressed tissues, Biomacromolecules, 14 (2013) 3808-3819.

[242] G. Riley, V. Curry, J. DeGroot, B. van El, N. Verzijl, B. Hazleman, R. Bank, Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology, Matrix Biol, 21 (2002) 185-195.

[243] M. Attia, E. Huet, C. Gossard, S. Menashi, M. Tassoni, I. Martelly, Early events of overused supraspinatus tendons involve matrix metalloproteinases and EMMPRIN/CD147 in the absence of inflammation, Am J Sports Med, 41 (2013) 908-917.

[244] E. Karousou, M. Ronga, D. Vigetti, A. Passi, N. Maffulli, Collagens, proteoglycans, MMP-2, MMP-9 and TIMPs in human Achilles tendon rupture, Clin Orthop Relat Res, 466 (2008) 1577-1582.

[245] T. Jarvinen, T. Jarvinen, P. Kannus, L. Jozsa, M. Jarvinen, Collagen fibres of the spontaneously ruptured human tendons display decrease thickness and crimp angle, Journal of Orthopaedic Research, 22 (2004) 1303-1309.

[246] R.C. Haut, The influence of specimen length on the tensile failure properties of tendon collagen, Journal of Biomechanics, 19 (1986) 951-955.

[247] Y. Lanir, Structure-strength relations in mammalian tendon, Biophysical Journal, 24 (1978) 541-554.

[248] C. Boote, S. Dennis, Y. Huang, A. Quantock, K. Meek, Lamellar orientation in human cornea in relation to mechanical properties, Journal of Structural Biology, 149 (2005) 1-6.

[249] E.G. Canty, K.E. Kadler, Collagen fibril biosynthesis in tendon: A review and recent insights, Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology, 133 (2002) 979-985. [250] C.S. Osborne, J.C. Barbenel, D. Smith, M. Savakis, M.H. Grant, Investigation into the tensile properties of collagen/chondroitin-6-sulphate gels: The effect of crosslinking agents and diamines, Medical & Biological Engineering & Computing, 36 (1998) 129-134.

[251] L.H.H.O. Damink, P.J. Dijkstra, M.J.A. van Luyn, P.B. van Wachem, P. Nieuwenhuis, J. Feijen, Crosslinking of dermal sheep collagen using hexamethylene diisocyanate, Journal of Materials Science: Materials in Medicine, 6 (1995) 429-434.

[252] D.F. Holmes, H.K. Graham, K.E. Kadler, Collagen fibrils forming in developing tendon show an early and abrupt limitation in diameter at the growing tips, Journal of Molecular Biology, 283 (1998) 1049-1058.

[253] J. Trotter, T. Koob, Collagen and proteoglycan in a sea urchin

ligament with mutable mechanical properties, Cell Tissue Res, 258 (1989) 527-539.

[254] K.A. Derwin, L.J. Soslowsky, J.H. Kimura, A.H. Plaas, Proteoglycans and glycosaminoglycan fine structure in the mouse tail tendon fascicle, Journal of Orthopaedic Research, 19 (2001) 269-277.

[255] E. Reichenberger, B.R. Olsen, Collagens as organizers of extracellular matrix during morphogenesis, Seminars in Cell and Developmental Biology, 7 (1996) 631-638.

[256] S. Hsu, A.M. Jamieson, J. Blackwell, Viscoelastic studies of extracellular matrix interactions in a model native collagen gel system, Biorheology, 31 (1994) 21-36.

[257] G.D. Pins, F.H. Silver, A self-assembled collagen scaffold suitable for use in soft and hard tissue replacement, Materials Science and Engineering: C, 3 (1995) 101-107.

[258] M.C. Wang, G.D. Pins, F.H. Silver, Collagen fibres with improved strength for the repair of soft tissue injuries, Biomaterials, 15 (1994) 507-512.

[259] Y.P. Kato, D.L. Christiansen, R.A. Hahn, S.-J. Shieh, J.D. Goldstein, F.H. Silver, Mechanical properties of collagen fibres: A comparison of reconstituted and rat tail tendon fibres, Biomaterials, 10 (1989) 38-42.

[260] G.E. Attenburrow, D.C. Bassett, Compliances and failure modes of oriented chain-extended polyethylene, Journal of Materials Science, 14 (1979) 2679-2687.

[261] B.J. Rigby, N. Hirai, J.D. Spikes, H. Eyring, The mechanical properties of rat tail tendon, The Journal of General Physiology, 43 (1959) 265-283.

[262] D.G. Hepworth, J.P. Smith, The mechanical properties of composites manufactured from tendon fibres and pearl glue (animal glue), Composites Part A: Applied Science and Manufacturing, 33 (2002) 797-803.

[263] J.M. Garcia Paez, E. Jorge Herrero, A. Carrera Sanmartin, I. Millan, A. Cordon, M. Martin Maestro, A. Rocha, B. Arenaz, J.L. Castillo-Olivares, Comparison of the mechanical behaviors of

biological tissues subjected to uniaxial tensile testing: Pig, calf and ostrich pericardium sutured with Gore-Tex, Biomaterials, 24 (2003) 1671-1679.

[264] E. Gentleman, A.N. Lay, D.A. Dickerson, E.A. Nauman, G.A. Livesay, K.C. Dee, Mechanical characterization of collagen fibers and scaffolds for tissue engineering, Biomaterials, 24 (2003) 3805-3813.

[265] A. Viidik, Rheology of skin with special reference to age-related parameters and their possible correlation to structure., in: Robert, L. (Ed.) Frontier of Matrix Biology. Aging of connective tissue skin, Karger, Basel1973, pp. 157-189.

[266] D.P. Knight, L. Nash, X.W. Hu, J. Haffegee, M.W. Ho, In vitro formation by reverse dialysis of collagen gels containing highly oriented arrays of fibrils, Journal of Biomedical Materials Research, 41 (1998) 185-191.

[267] G.E. Attenburrow, The rheology of leather - A review, Journal of the Society of Leather Technologists and Chemists, 77 (1993) 107-114.

[268] P. Fratzl, K. Misof, I. Zizak, G. Rapp, H. Amenitsch, S. Bernstorff, Fibrillar structure and mechanical properties of collagen, Journal of Structural Biology, 122 (1997) 119-122.

[269] F.H. Silver, D.L. Christiansen, P.B. Snowhill, Y. Chen, Transition from viscous to elasticbased dependency of mechanical properties of self-assembled type I collagen fibers, Journal of Applied Polymer Science, 79 (2001) 134-142.

[270] G.D. Pins, D.L. Christiansen, R. Patel, F.H. Silver, Self-assembly of collagen fibers. Influence of fibrillar alignment and decorin on mechanical properties., Biophysical Journal, 73 (1997) 2164-2172.

[271] P.P. Purslow, T.J. Wess, D.W.L. Hukins, Collagen orientation and molecular spacing during creep and stress-relaxation in soft connective tissues, The Journal of Experimental Biology, 201 (1998) 135-142.

[272] L.J. Gathercole, A. Keller, Early development of crimping in rat tail tendon collagen: A polarizing optical and SEM study, Micron, 9 (1978) 83-89.

[273] I.F. Williams, A.S. Craig, D.A.D. Parry, A.E. Goodship, J. Shah, I.A. Silver, Development of collagen fibril organization and collagen crimp patterns during tendon healing, International Journal of Biological Macromolecules, 7 (1985) 275-282.

[274] D.A.D. Parry, The molecular fibrillar structure of collagen and its relationship to the mechanical properties of connective tissue, Biophysical Chemistry, 29 (1988) 195-209.

[275] A.M. Cribb, J.E. Scott, Tendon response to tensile stress: An ultrastructural investigation of collagen:proteoglycan interactions in stressed tendon, Journal of Anatomy, 187 (1995) 423-428.

[276] S.E. Langdon, R. Chernecky, C.A. Pereira, D. Abdulla, J.M. Lee, Biaxial mechanical/structural effects of equibiaxial strain during crosslinking of bovine pericardial xenograft materials, Biomaterials, 20 (1999) 137-153.

[277] H.-W. Sung, Y. Chang, C.-T. Chiu, C.-N. Chen, H.-C. Liang, Mechanical properties of a porcine aortic valve fixed with a naturally occurring crosslinking agent, Biomaterials, 20 (1999) 1759-1772.

[278] S.P. Magnusson, K. Qvortrup, J.O. Larsen, S. Rosager, P. Hanson, P. Aagaard, M. Krogsgaard, M. Kjaer, Collagen fibril size and crimp morphology in ruptured and intact Achilles tendons, Matrix Biology, 21 (2002) 369-377.

[279] M. Raspanti, A. Manelli, M. Franchi, A. Ruggeri, The 3D structure of crimps in the rat Achilles tendon, Matrix Biology, 24 (2005) 503-507.

[280] M. Franchi, M. Fini, M. Quaranta, V.D. Pasquale, M. Raspanti, G. Giavaresi, V. Ottani, A. Ruggeri, Crimp morphology in relaxed and stretched rat Achilles tendon, Journal of Anatomy, 210 (2007) 1-7.

[281] P. Fratzl, R. Weinkamer, Nature's hierarchical materials, Progress in Materials Science, 52 (2007) 1263-1334.

[282] A. Bailey, N. Light, Connective tissue in meat and meat products, Elsevier Applied Science, London and New York, 1989.

[283] F.H. Silver, D.L. Christiansen, P.B. Snowhill, Y. Chen, Role of storage on changes in the mechanical properties of tendon and self-assembled collagen fibres, Connective Tissue Research, 41 (2000) 155-164.

[284] N. Sasaki, S. Odajima, Elongation mechanism of collagen fibrils and force-strain relations of tendon at each level of structural hierarchy, Journal of Biomechanics, 29 (1996) 1131-1136.

[285] Y.P. Kato, F.H. Silver, Formation of continuous collagen fibres: Evaluation of biocompatibility and mechanical properties, Biomaterials, 11 (1990) 169-175.

[286] K.B. Freedman, M.J. D'Amato, D.D. Nedeff, A. Kaz, B.R. Bach, Arthroscopic anterior cruciate ligament reconstruction: A metaanalysis comparing patellar tendon and hamstring tendon autografts, Am J Sports Med, 31 (2003) 2-11.

[287] J.P. Goldblatt, S.E. Fitzsimmons, E. Balk, J.C. Richmond, Reconstruction of the anterior cruciate ligament: Meta-analysis of patellar tendon versus hamstring tendon autograft, Arthroscopy, 21 (2005) 791-803.

[288] J.S. Mulford, S.E. Hutchinson, J.R. Hang, Outcomes for primary anterior cruciate reconstruction with the quadriceps autograft: A systematic review, Knee Surgery, Sports Traumatology, Arthroscopy, 21 (2013) 1882-1888.

[289] T. Moore, B. Anderson, J.G. Seiler, Flexor tendon reconstruction, Journal of Hand Surgery-American Volume, 35A (2010) 1025-1030.

[290] S. Ichioka, K. Harii, A. Yamada, Y. Sugiura, Tendinocutaneous free flap transfer to cover an extensive skin-tendon defect of the dorsum of the hand: case report, The Journal of Trauma, 36 (1994) 901-903.

[291] R. Adani, I. Marcoccio, L. Tarallo, Flap coverage of dorsum of hand associated with extensor tendons injuries: A completely vascularized single-stage reconstruction, Microsurgery, 23 (2003) 32-39.

[292] S.W. Kim, J.P. Hong, W.J. Lee, Y.K. Chung, K.C. Tark, Single-stage Achilles tendon reconstruction using a composite sensate free flap of dorsalis pedis and tendon strips of the extensor digitorum longus in a complex wound, Annals of Plastic Surgery, 50 (2003) 653-757.

[293] D.A. McGuire, S.D. Hendricks, Allografts in sports medicine, Operative Techniques in Sports Medicine, 15 (2007) 46-52.

[294] P.M. Prokopis, A.A. Schepsis, Allograft use in ACL reconstruction, Knee, 6 (1999) 75-85.

[295] E. Olender, I. Uhrynowska-Tyszkiewicz, A. Kaminski, Revitalization of biostatic tissue allografts: new perspectives in tissue transplantology, Transplantation Proceedings, 43 (2011) 3137-3141.

[296] G.C. Fanelli, J.D. Beck, C.J. Edson, Single compared to double-bundle PCL reconstruction using allograft tissue, The Journal of Knee Surgery, 25 (2012) 59-64.

[297] C.Y.L. Woon, S. Farnebo, T. Schmitt, A. Kraus, K. Megerle, H. Pham, X.R. Yan, S.S. Gambhir, J. Chang, Human flexor tendon tissue engineering: revitalization of biostatic allograft scaffolds, Tissue Engineering Part A, 18 (2012) 2406-2417.

[298] C. Giuglea, C. Coman, S. Marinescu, I. Florescu, I. Lascar, Transplantation of composite tissue allograft: scientific bases and clinical applications, Journal of Medicine and Life, 6 (2013) 40-44.

[299] V. Mehta, C. Mandala, D. Foster, T. Petsche, Comparison of revision rates in bone-patella tendon-bone autograft and allograft anterior cruciate ligament reconstruction, Orthopedics, 33 (2010) 12.

[300] H.O. Mayr, D. Willkomm, A. Stoehr, M. Schettle, N.P. Suedkamp, A. Bernstein, R. Hube, Revision of anterior cruciate ligament reconstruction with patellar tendon allograft and autograft: 2and 5-year results, Archives of Orthopaedic and Trauma Surgery, 132 (2012) 867-874.

[301] P.A. Indelicato, M.G. Ciccotti, J. Boyd, L.D. Higgins, B.S. Shaffer, C.T. Vangsness, Aseptically processed and chemically sterilized BTB allografts for anterior cruciate ligament reconstruction: A prospective randomized study, Knee Surgery, Sports Traumatology, Arthroscopy, 21 (2013) 2107-2112.

[302] H. Li, H.Y. Tao, S.S. Cho, S. Chen, Z.J. Yao, S.Y. Chen, Difference in graft maturity of the reconstructed anterior cruciate ligament 2 years postoperatively a comparison between autografts and allografts in young men using clinical and 3.0-T magnetic resonance imaging evaluation, Am J Sports Med, 40 (2012) 1519-1526.

[303] M. Pallis, S.J. Svoboda, K.L. Cameron, B.D. Owens, Survival comparison of allograft and autograft anterior cruciate ligament reconstruction at the United States Military Academy, Am J Sports Med, 40 (2012) 1242-1246.

[304] C.F. van Eck, J.G. Schkrohowsky, Z.M. Working, J.J. Irrgang, F.H. Fu, Prospective analysis of failure rate and predictors of failure after anatomic anterior cruciate ligament reconstruction with allograft, Am J Sports Med, 40 (2012) 800-807.

[305] M.T. Cooper, C. Kaeding, Comparison of the hospital cost of autograft versus allograft softtissue anterior cruciate ligament reconstructions, Arthroscopy, 26 (2010) 1478-1482.

[306] S.H. Nagda, G.G. Altobelli, K.A. Bowdry, C.E. Brewster, S.J. Lombardo, Cost analysis of outpatient anterior cruciate ligament reconstruction: Autograft versus allograft, Clin Orthop Relat Res, 468 (2010) 1418-1422.

[307] J. Chen, J. Xu, A. Wang, M. Zheng, Scaffolds for tendon and ligament repair: Review of the efficacy of commercial products, Expert Review of Medical Devices, 6 (2009) 61-73.

[308] N.J. Turner, S.F. Badylak, Biologic scaffolds for musculotendinous tissue repair, European Cells & Materials, 25 (2013) 130-143.

[309] D.K. Lee, A preliminary study on the effects of acellular tissue graft augmentation in acute Achilles tendon ruptures, The Journal of Foot and Ankle Surgery, 47 (2008) 8-12.

[310] C.J. Vansteensel, O. Schreuder, B.F. Vandenbosch, H.C. Vanpaassen, H.E. Menke, G. Voorhorst, S. Gratama, Failure of anterior-ligament reconstruction using tendon xenograft, Journal of Bone and Joint Surgery-American Volume, 69A (1987) 860-864.

[311] L.J. Dahlstedt, P. Netz, N. Dalen, Poor results of bovine xenograft for knee cruciate ligament repair, Acta Orthop Scand, 60 (1989) 3-7.

[312] K.R. Stone, U.M. Abdel-Motal, A.W. Walgenbach, T.J. Turek, U. Galili, Replacement of human. anterior cruciate ligaments with pig ligaments: A model for anti-non-gal antibody response in long-term xenotransplantation, Transplantation, 83 (2007) 211-219.

[313] J.A. Soler, S. Gidwani, M.J. Curtis, Early complications from the use of porcine dermal collagen implants (Permacol (TM)) as bridging constructs in the repair of massive rotator cuff tears - A report of 4 cases, Acta Orthopaedica Belgica, 73 (2007) 432-436.

[314] F.R. Noyes, S.D. BarberWestin, Reconstruction of the anterior cruciate ligament with human allograft - Comparison of early and later results, Journal of Bone and Joint Surgery-American Volume, 78A (1996) 524-537.

[315] J. Marrale, M.C. Morrissey, F.S. Haddad, A literature review of autograft and allograft anterior cruciate ligament reconstruction, Knee Surgery, Sports Traumatology, Arthroscopy, 15 (2007) 690-704.

[316] U. Galili, Induced anti-non gal antibodies in human xenograft recipients, Transplantation, 93 (2012) 11-16.

[317] J. Ikeda, C.F. Zhao, Q.S. Chen, A.R. Thoreson, K.N. An, P.C. Amadio, Compressive properties of cd-HA-gelatin modified intrasynovial tendon allograft in canine model in vivo, Journal of Biomechanics, 44 (2011) 1793-1796.

[318] F.E. Karabekmez, C.F. Zhao, Surface treatment of flexor tendon autograft and allograft decreases adhesion without an effect of graft cellularity: a pilot study, Clin Orthop Relat Res, 470 (2012) 2522-2527.

[319] G.M. Thornton, X.X. Shao, M.E. Kuchison, L.L. Marchuk, N.G. Shrive, C.B. Frank, Healing ligament mechanical properties are improved by repair with interpositional allografts but not by concomitant treatment with hyaluronic acid, Journal of Orthopaedic Research, 27 (2009) 400-407.

[320] P. Basile, T. Dadali, J. Jacobson, S. Hasslund, M. Ulrich-Vinther, K. Soballe, Y. Nishio, M.H. Drissi, H.N. Langstein, D.J. Mitten, R.J. O'Keefe, E.M. Schwarz, H.A. Awad, Freeze-dried tendon allografts as tissue-engineering scaffolds for gdf5 gene delivery, Molecular Therapy, 16 (2008) 466-473.

[321] J. Thorfinn, I.K. Angelidis, L. Gigliello, H.M. Pham, D. Lindsey, J. Chang, Bioreactor optimization of tissue engineered rabbit flexor tendons in vivo, Journal of Hand Surgery-European Volume, 37E (2012) 109-114.

[322] H. Omae, C.F. Zhao, Y.L. Sun, K.N. An, P.C. Amadio, Multilayer tendon slices seeded with bone marrow stromal cells: A novel composite for tendon engineering, Journal of Orthopaedic Research, 27 (2009) 937-942.

[323] G.S. Kryger, A.K.S. Chong, M. Costa, H. Pham, S.J. Bates, J. Chang, A comparison of tenocytes and mesenchymal stem cells for use in flexor tendon tissue engineering, The Journal of Hand Surgery, 32 (2007) 597-605.

[324] L. Ketchum, Suture materials and suture techniques used in tendon repair, Hand Clin, 1 (1985) 43-53.

[325] A. Kara, H. Celik, A. Seker, M.A. Uysal, M. Uzun, M. Malkoc, Granuloma formation secondary to Achilles tendon repair with nonabsorbable suture, Int J Surg Case Rep, 5 (2014) 720-722.

[326] W.B.J. Rudge, M. James, Flexor tendon injuries in the hand: A UK survey of repair techniques and suture materials. Are we following the evidence?, ISRN Plastic Surgery, 2014 (2014) 4.

[327] S. Rawson, S. Cartmell, J. Wong, Suture techniques for tendon repair: A comparative review, Muscles Ligaments Tendons Journal, 3 (2013) 220-228.

[328] T. Lawrence, T. Davis, A biomechanical analysis of suture materials and their influence on a four-strand flexor tendon repair, J Hand Surg Am, 30 (2005) 836-841.

[329] R.H. Gelberman, M.I. Boyer, M.D. Brodt, S.C. Winters, M.J. Silva, The effect of gap formation at the repair site on the strength and excursion of intrasynovial flexor tendons - An experimental study on the early stages of tendon-healing in dogs, Journal of Bone and Joint Surgery-American Volume, 81A (1999) 975-982.

[330] T. Peltz, R. Haddad, P. Scougall, M. Gianoutsos, N. Bertollo, W. Walsh, Performance of a knotless four-strand flexor tendon repair with a unidirectional barbed suture device: A dynamic ex vivo comparison, J Hand Surg Eur Vol, 39 (2014) 30-39.

[331] P. Parikh, S. Davison, J. Higgins, Barbed suture tenorrhaphy: An ex vivo biomechanical analysis, Plast Reconstr Surg, 124 (2009) 1551-1558.

[332] W. McClellan, M. Schessler, D. Ruch, L. Levin, R. Goldner, A knotless flexor tendon repair technique using a bidirectional barbed suture: An ex vivo comparison of three methods, Plast Reconstr Surg, 128 (2011) 322-327.

[333] C. Joyce, K. Whately, J. Chan, M. Murphy, F. O'Brien, S. Carroll, Flexor tendon repair: A comparative study between a knotless barbed suture repair and a traditional four-strand monofilament suture repair, J Hand Surg Eur Vol, 39 (2014) 40-45.

[334] C. Joyce, C. Sugrue, J. Chan, L. Delgado, D. Zeugolis, S. Carroll, J. Kelly, A barbed suture repair for flexor tendons: A novel technique with no exposed barbs, Plast Reconstr Surg Glob Open, (In Press).

[335] S.S. Burkhart, J.L. Diaz Pagan, M.A. Wirth, K.A. Athanasiou, Cyclic loading of anchor-based rotator cuff repairs: Confirmation of the tension overload phenomenon and comparison of suture anchor fixation with transosseous fixation, Arthroscopy, 13 (1997) 720-724.

[336] S.S. Burkhart, T.C. Johnson, M.A. Wirth, K.A. Athanasiou, Cyclic loading of transosseous rotator cuff repairs: Tension overload as a possible cause of failure, Arthroscopy, 13 (1997) 172-176.

[337] M. Stalder, M. Farshad, J.G. Snedeker, D.C. Meyer, Interference screws should be shorter than the hamstring tendon graft in the bone tunnel for best fixation, Knee Surgery, Sports Traumatology, Arthroscopy, 21 (2013) 584-588.

[338] R.A. Magnussen, R.R. Glisson, C.T. Moorman, 3rd, Augmentation of Achilles tendon repair with extracellular matrix xenograft: A biomechanical analysis, Am J Sports Med, 39 (2011) 1522-1527.

[339] A. Leonardi, A. Duarte, N. Severino, Bone tunnel enlargement on anterior cruciate ligament reconstruction, Acta Ortop Bras, 22 (2014) 240-244.

[340] M. Kobayashi, Y. Nakagawa, T. Suzuki, S. Okudaira, T. Nakamura, A retrospective review of bone tunnel enlargement after anterior cruciate ligament reconstruction with hamstring tendons fixed with a metal round cannulated interference screw in the femur, Arthroscopy, 22 (2006) 1093-1099.

[341] C. Shen, S. Jiang, L. Jiang, L. Dai, Bioabsorbable versus metallic interference screw fixation in anterior cruciate ligament reconstruction: A meta-analysis of randomized controlled trials, Arthroscopy, 26 (2010) 705-713.

[342] F. Adam, D. Pape, K. Schiel, O. Steimer, D. Kohn, S. Rupp, Biomechanical properties of patellar and hamstring graft tibial fixation techniques in anterior cruciate ligament reconstruction: Experimental study with roentgen stereometric analysis, Am J Sports Med, 32 (2004) 71-78.

[343] J.C. Brand, Jr., J. Nyland, D.N. Caborn, D.L. Johnson, Soft-tissue interference fixation: Bioabsorbable screw versus metal screw, Arthroscopy, 21 (2005) 911-916.

[344] P. Ntagiopoulos, G. Demey, T. Tavernier, D. Dejour, Comparison of resorption and remodeling of bioabsorbable interference screws in anterior cruciate ligament reconstruction, Int Orthop, (In Press).

[345] D.C. Meyer, M. Stalder, P.P. Koch, J.G. Snedeker, M. Farshad, Contact pressure on ACL hamstring grafts in the bone tunnel with interference screw fixation -- Dynamic adaptation under load, Knee, 19 (2012) 676-679.

[346] A. Weiler, M. Richter, G. Schmidmaier, F. Kandziora, N.P. Sudkamp, The EndoPearl device increases fixation strength and eliminates construct slippage of hamstring tendon grafts with interference screw fixation, Arthroscopy, 17 (2001) 353-359.

[347] X. Liu, W. Wu, Y. Fang, M. Zhang, W. Huang, Biomechanical comparison of osteoporotic distal radius fractures fixed by distal locking screws with different length, PLoS One, 9 (2014) e103371.

[348] S. Konan, F. Haddad, A clinical review of bioabsorbable interference screws and their adverse effects in anterior cruciate ligament reconstruction surgery, Knee, 16 (2009) 6-13.

[349] K. Atesok, F. Fu, M. Wolf, M. Ochi, L. Jazrawi, M. Doral, J. Lubowitz, S. Rodeo, Augmentation of tendon-to-bone healing, J Bone Joint Surg Am, 96 (2014) 513-521.

[350] S.J. Kew, J.H. Gwynne, D. Enea, M. Abu-Rub, A. Pandit, D. Zeugolis, R.A. Brooks, N. Rushton, S.M. Best, R.E. Cameron, Regeneration and repair of tendon and ligament tissue using collagen fibre biomaterials, Acta Biomaterialia, 7 (2011) 3237-3247.

[351] N. Juncosa-Melvin, K.S. Matlin, R.W. Holdcraft, V.S. Nirmalanandhan, D.L. Butler, Mechanical stimulation increases collagen type I and collagen type III gene expression of stem cell-collagen sponge constructs for patellar tendon repair, Tissue Engineering, 13 (2007) 1219-1226.

[352] D.L. Butler, C. Gooch, K.R. Kinneberg, G.P. Boivin, M.T. Galloway, V.S. Nirmalanandhan, J.T. Shearn, N.A. Dyment, N. Juncosa-Melvin, The use of mesenchymal stem cells in collagenbased scaffolds for tissue-engineered repair of tendons, Nature Protocols, 5 (2010) 849-863.

[353] S.R. Caliari, B.A. Harley, The effect of anisotropic collagen-GAG scaffolds and growth factor supplementation on tendon cell recruitment, alignment, and metabolic activity, Biomaterials, 32 (2011) 5330-5340.

[354] S.R. Caliari, D.W. Weisgerber, M.A. Ramirez, D.O. Kelkhoff, B.A.C. Harley, The influence of collagen-glycosaminoglycan scaffold relative density and microstructural anisotropy on tenocyte bioactivity and transcriptomic stability, Journal of the Mechanical Behavior of Biomedical Materials, 11 (2012) 27-40.

[355] S.R. Caliari, B. Harley, Composite growth factor supplementation strategies to enhance tenocyte bioactivity in aligned collagen GAG scaffolds, Tissue Engineering Part A, 19 (2013) 1100-1112.

[356] Y. Liu, H.S. Ramanath, D.A. Wang, Tendon tissue engineering using scaffold enhancing strategies, Trends in Biotechnology, 26 (2008) 201-209.

[357] D.I. Zeugolis, R.G. Paul, G. Attenburrow, Engineering extruded collagen fibers for biomedical applications, Journal of Applied Polymer Science, 108 (2008) 2886-2894.

[358] D.I. Zeugolis, R.G. Paul, G. Attenburrow, Extruded collagen-polyethylene glycol fibers for tissue engineering applications, Journal of Biomedical Materials Research Part B Applied Biomaterials, 85B (2008) 343-352.

[359] D.I. Zeugolis, G.R. Paul, G. Attenburrow, Cross-linking of extruded collagen fibers-A biomimetic three-dimensional scaffold for tissue engineering applications, Journal of Biomedical Materials Research Part A, 89A (2009) 895-908.

[360] C. Theisen, S. Fuchs-Winkelmann, K. Knappstein, T. Efe, J. Schmitt, J. Paletta, M. Schofer, Influence of nanofibers on growth and gene expression of human tendon derived fibroblast, Biomedical Engineering Online, 9 (2010) 9.

[361] V. Kishore, J. Uquillas, A. Dubikovsky, M. Alshehabat, P. Snyder, G. Breur, O. Akkus, In vivo response to electrochemically aligned collagen bioscaffolds, Journal of Biomedical Materials Research Part B Applied Biomaterials, 100 (2012) 400-408.

[362] W.T. Daly, L. Yao, M.T. Abu-rub, C. O'Connell, D.I. Zeugolis, A.J. Windebank, A.S. Pandit, The effect of intraluminal contact mediated guidance signals on axonal mismatch during peripheral nerve repair, Biomaterials, 33 (2012) 6660-6671. [363] D. Enea, J. Gwynne, S. Kew, M. Arumugam, J. Shepherd, R. Brooks, S. Ghose, S. Best, R. Cameron, N. Rushton, Collagen fibre implant for tendon and ligament biological augmentation. In vivo study in an ovine model, Knee Surgery, Sports Traumatology, Arthroscopy, 21 (2013) 1783-1793.

[364] X. Cheng, U.A. Gurkan, C.J. Dehen, M.P. Tate, H.W. Hillhouse, G.J. Simpson, O. Akkus, An electrochemical fabrication process for the assembly of anisotropically oriented collagen bundles, Biomaterials, 29 (2008) 3278-3288.

[365] D. Denning, M.T. Abu-Rub, D.I. Zeugolis, S. Habelitz, P. A., A. Fertala, B.J. Rodriguez, Electromechanical properties of dried tendon and iso-electrically focused collagen hydrogels, Acta Biomaterialia, 8 (2012) 3073-3079.

[366] M.T. Abu-Rub, K.L. Billiar, M.H. van Es, A. Knight, B.J. Rodriguez, D.I. Zeugolis, S. McMahon, A.J. Windebank, A. Pandit, Nano-textured self-assembled aligned collagen hydrogels promote directional neurite guidance and overcome inhibition by myelin associated glycoprotein, Soft Matter, 7 (2011) 2770-2781.

[367] V. Kishore, W. Bullock, X. Sun, W.S. Van Dyke, O. Akkus, Tenogenic differentiation of human MSCs induced by the topography of electrochemically aligned collagen threads, Biomaterials, 33 (2012) 2137-2144.

[368] U.A. Gurkan, X. Cheng, V. Kishore, J.A. Uquillas, O. Akkus, Comparison of morphology, orientation, and migration of tendon derived fibroblasts and bone marrow stromal cells on electrochemically aligned collagen constructs, Journal of Biomedical Materials Research Part A, 94 (2010) 1070-1079.

[369] L.D. Bellincampi, R.F. Closkey, R. Prasad, J.P. Zawadsky, M.G. Dunn, Viability of fibroblast-seeded ligament analogs after autogenous implantation, Journal of Orthopaedic Research, 16 (1998) 414-420.

[370] E. Gentleman, E.A. Nauman, G.A. Livesay, K.C. Dee, Collagen composite biomaterials resist contraction while allowing development of adipocytic soft tissue in vitro, Tissue Engineering, 12 (2006) 1639-1649.

[371] J.A. Key, The treatment of fractures of the patella, The American Journal of Surgery, 44 (1939) 166-177.

[372] D.H. Hooker, C.R. Lam, Tendon injuries: A study of one hundred and sixteen cases, The American Journal of Surgery, 54 (1941) 412-416.

[373] G.H. Altman, F. Diaz, C. Jakuba, T. Calabro, R.L. Horan, J. Chen, H. Lu, J. Richmond, D.L. Kaplan, Silk-based biomaterials, Biomaterials, 24 (2003) 401-416.

[374] C. Vepari, D.L. Kaplan, Silk as a biomaterial, Progress in Polymer Science, 32 (2007) 991-1007.
[375] M.J. Buehler, S. Keten, T. Ackbarow, Theoretical and computational hierarchical nanomechanics of protein materials: Deformation and fracture, Progress in Materials Science, 53 (2008) 1101-1241.

[376] G.H. Altman, R.L. Horan, H.H. Lu, J. Moreau, I. Martin, J.C. Richmond, D.L. Kaplan, Silk matrix for tissue engineered anterior cruciate ligaments, Biomaterials, 23 (2002) 4131-4141.

[377] T. Kardestuncer, M.B. McCarthy, V. Karageorgiou, D. Kaplan, G. Gronowicz, RGD-tethered silk substrate stimulates the differentiation of human tendon cells, Clin Orthop Relat Res, 448 (2006) 234-239.

[378] Y.K. Seo, J.K. Park, K.Y. Song, S.Y. Kwon, H.S. Lee, Wound healing effect of collagenhyaluronic acid implanted in partially injured anterior cruciate ligament of dog, Biotechnology and Bioprocess Engineering, 15 (2010) 552-558.

[379] Y.K. Seo, H.H. Youn, J.K. Park, K.Y. Song, S.Y. Kwon, H.S. Lee, Effect of collagen-GAG on the anterior cruciate ligament regeneration of rabbit, Tissue Engineering and Regenerative Medicine, 7 (2010) 548-555.

[380] T.K.H. Teh, S.L. Toh, J.C.H. Goh, Aligned fibrous scaffolds for enhanced mechanoresponse and tenogenesis of mesenchymal stem cells, Tissue Engineering Part A, 19 (2013) 1360-1372.

[381] H. Fan, H. Liu, S.L. Toh, J.C. Goh, Anterior cruciate ligament regeneration using mesenchymal stem cells and silk scaffold in large animal model, Biomaterials, 30 (2009) 4967-4977.

[382] I. Foster, Z. Ralis, B. McKibbin, D. Jenkins, Biological reaction to carbon fiber implants: The formation and structure of a carbon-induced "neotendon", Clin Orthop Relat Res, 131 (1978) 299-307.

[383] T. Majima, T. Funakosi, N. Iwasaki, S.T. Yamane, K. Harada, S. Nonaka, A. Minami, S. Nishimura, Alginate and chitosan polyion complex hybrid fibers for scaffolds in ligament and tendon tissue engineering, Journal of Orthopaedic Science, 10 (2005) 302-307.

[384] Y.C. Lin, F.J. Tan, K.G. Marra, S.S. Jan, D.C. Liu, Synthesis and characterization of collagen/hyaluronan/chitosan composite sponges for potential biomedical applications, Acta Biomaterialia, 5 (2009) 2591-2600.

[385] P.O. Bagnaninchi, Y. Yang, N. Zghoul, N. Maffulli, R.K. Wang, A.J. Haj, Chitosan microchannel scaffolds for tendon tissue engineering characterized using optical coherence tomography, Tissue Engineering, 13 (2007) 323-331.

[386] T. Funakoshi, T. Majima, N. Iwasaki, N. Suenaga, N. Sawaguchi, K. Shimode, A. Minami, K. Harada, S. Nishimura, Application of tissue engineering techniques for rotator cuff regeneration using a chitosan-based hyaluronan hybrid fiber scaffold, Am J Sports Med, 33 (2005) 1193-1201.

[387] T. Funakoshi, T. Majima, N. Iwasaki, S. Yamane, T. Masuko, A. Minami, K. Harada, H. Tamura, S. Tokura, S. Nishimura, Novel chitosan-based hyaluronan hybrid polymer fibers as a scaffold in ligament tissue engineering, Journal of Biomedical Materials Research Part A, 74 (2005) 338-346.

[388] Q.W. Guo-Qiang Chen, The application of polyhydroxyalkanoates as tissue engineering materials, Biomaterials, 26 (2005) 6565-6578.

[389] W.R. Webb, T.P. Dale, A.J. Lomas, G. Zeng, I. Wimpenny, A.J. El Haj, N.R. Forsyth, G.-Q. Chen, The application of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) scaffolds for tendon repair in the rat model, Biomaterials, 34 (2013) 6683-6694.

[390] L.M. Delgado, A. Pandit, D.I. Zeugolis, Influence of sterilisation methods on collagen-based devices stability and properties, Expert Review of Medical Devices, 11 (2014) 305-314.

[391] Y. Tabata, The importance of drug delivery systems in tissue engineering, Pharmaceutical Science & Technology Today, 3 (2000) 80-89.

[392] I. Schroven, S. Geens, L. Beckers, W. Lagrange, G. Fabry, Experience with the Leeds-Keio artificial ligament for anterior cruciate ligament reconstruction, Knee Surgery, Sports Traumatology, Arthroscopy, 2 (1994) 214-218.

[393] A.W. Murray, M.F. Macnicol, 10-16 year results of Leeds-Keio anterior cruciate ligament reconstruction, Knee, 11 (2004) 9-14.

[394] S. Zaffagnini, G.M. Marcheggiani Muccioli, V. Chatrath, A. Bondi, V. De Pasquale, D. Martini, B. Bacchelli, M. Marcacci, Histological and ultrastructural evaluation of Leeds-Keio ligament 20 years after implant: A case report, Knee Surgery, Sports Traumatology, Arthroscopy, 16 (2008) 1026-1029.

[395] G. McPherson, H. Mendenhall, D. Gibbons, H. Plenk, W. Rottmann, J. Sanford, J. Kennedy, J. Roth, Experimental mechanical and histologic evaluation of the Kennedy ligament augmentation device, Clin Orthop Relat Res, 196 (1985) 186-195.

[396] H. Pinar, J. Gillquist, Dacron augmentation of a free patellar tendon graft: A biomechanical study, Arthroscopy, 5 (1989) 328-330.

[397] S.P. Arnoczky, R.F. Warren, J.P. Minei, Replacement of the anterior cruciate ligament using a synthetic prosthesis. An evaluation of graft biology in the dog, Am J Sports Med, 14 (1986) 1-6.

[398] H. Li, Y.S. Ge, P.Y. Zhang, L.X. Wu, S.Y. Chen, The effect of layer-by-layer chitosanhyaluronic acid coating on graft-to-bone healing of a poly(ethylene terephthalate) artificial ligament, Journal of Biomaterials Science-Polymer Edition, 23 (2012) 425-438.

[399] J. Aragona, J. Parsons, H. Alexander, A. Weiss, Soft tissue attachment of a filamentous carbon-absorbable polymer tendon and ligament replacement, Clinical Orthopeadics and Related Research, 160 (1981) 268-278.

[400] P.D. Evans, G.A. Pritchard, D.H.R. Jenkins, Carbon fibre used in the late reconstruction of rupture of the extensor mechanism of the knee, Injury, 18 (1987) 57-60.

[401] J.R. Parsons, A.B. Weiss, R.S. Schenk, H. Alexander, F. Pavlisko, Long-term follow-up of achilles tendon repair with an absorbable polymer carbon fiber composite, Foot & Ankle, 9 (1989) 179-184.

[402] S. Singh, H.S. Nalwa, Nanotechnology and health safety--toxicity and risk assessments of nanostructured materials on human health, Journal of Nanoscience and Nanotechnology, 7 (2007) 3048-3070.

[403] A.A. Shvedova, V. Castranova, E.R. Kisin, D. Schwegler-Berry, A.R. Murray, V.Z. Gandelsman, A. Maynard, P. Baron, Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells, Journal of Toxicology and Environmental Health. Part A, 66 (2003) 1909-1926.

[404] H.S. Yoo, T.G. Kim, T.G. Park, Surface-functionalized electrospun nanofibers for tissue engineering and drug delivery, Advanced Drug Delivery Reviews, 61 (2009) 1033-1042.

[405] D. Braghirolli, D. Steffens, P. Pranke, Electrospinning for regenerative medicine: A review of the main topics, Drug Discov Today, 19 (2014) 743-753.

[406] K. Fuller, A. Pandit, D. Zeugolis, The multifaceted potential of electro-spinning in regenerative medicine, Pharmaceutical Nanotechnology, 2 (2014) 23-34.

[407] A. Szentivanyi, T. Chakradeo, H. Zernetsch, B. Glasmacher, Electrospun cellular microenvironments: Understanding controlled release and scaffold structure, Advanced Drug Delivery Reviews, 63 (2011) 209-220.

[408] W. Liu, S. Thomopoulos, Y. Xia, Electrospun nanofibers for regenerative medicine, Advanced Healthcare Materials, 1 (2012) 10-25.

[409] X. Hu, S. Liu, G. Zhou, Y. Huang, Z. Xie, X. Jing, Electrospinning of polymeric nanofibers for drug delivery applications, Journal of Controlled Release, 185 (2014) 12-21.

[410] A. Oryan, A. Moshiri, A. Parizi Meimandi, I.A. Silver, A long-term in vivo investigation on the effects of xenogenous based, electrospun, collagen implants on the healing of experimentallyinduced large tendon defects, Journal of Musculoskeletal & Neuronal Interactions, 13 (2013) 353-367.

[411] D.I. Zeugolis, S.T. Khew, E.S.Y. Yew, A.K. Ekaputra, Y.W. Tong, L.-Y.L. Yung, D.W. Hutmacher, C. Sheppard, M. Raghunath, Electro-spinning of pure collagen nano-fibres - Just an expensive way to make gelatin?, Biomaterials, 29 (2008) 2293-2305.

[412] L. Yang, C.F.C. Fitie, K.O. van der Werf, M.L. Bennink, P.J. Dijkstra, J. Feijen, Mechanical properties of single electrospun collagen type I fibers, Biomaterials, 29 (2008) 955-962.

[413] D. Cao, W. Liu, X. Wei, F. Xu, L. Cui, Y. Cao, In vitro tendon engineering with avian tenocytes and polyglycolic acids: A preliminary report, Tissue Engineering, 12 (2006) 1369-1377.

[414] B. Wang, W. Liu, Y. Zhang, Y. Jiang, W.J. Zhang, G. Zhou, L. Cui, Y. Cao, Engineering of extensor tendon complex by an ex vivo approach, Biomaterials, 29 (2008) 2954-2961.

[415] W. Liu, B. Chen, D. Deng, F. Xu, L. Cui, Y. Cao, Repair of tendon defect with dermal fibroblast engineered tendon in a porcine model, Tissue Engineering, 12 (2006) 775-788.

[416] D. Deng, W. Liu, F. Xu, Y. Yang, G. Zhou, W.J. Zhang, L. Cui, Y. Cao, Engineering human neo-tendon tissue in vitro with human dermal fibroblasts under static mechanical strain, Biomaterials, 30 (2009) 6724-6730.

[417] H.W. Ouyang, J.C.H. Goh, A. Thambyah, S.H. Teoh, E.H. Lee, Knitted poly-lactide-coglycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon, Tissue Engineering, 9 (2003) 431-439.

[418] R. James, S. Kumbar, C. Laurencin, G. Balian, A. Chhabra, Tendon tissue engineering: Adipose-derived stem cell and GDF-5 mediated regeneration using electrospun matrix systems, Biomedical Materials, 6 (2011) 025011.

[419] S. Sahoo, L.T. Ang, J.C.H. Goh, S.L. Toh, Bioactive nanofibers for fibroblastic differentiation of mesenchymal precursor cells for ligament/tendon tissue engineering applications, Differentiation, 79 (2010) 102-110.

[420] S. Liu, M.J. Qin, C.M. Hu, F. Wu, W.G. Cui, T. Jin, C.Y. Fan, Tendon healing and antiadhesion properties of electrospun fibrous membranes containing bFGF loaded nanoparticles, Biomaterials, 34 (2013) 4690-4701.

[421] C.N. Manning, A.G. Schwartz, W. Liu, J. Xie, N. Havlioglu, S.E. Sakiyama-Elbert, M.J. Silva, Y. Xia, R.H. Gelberman, S. Thomopoulos, Controlled delivery of mesenchymal stem cells and growth factors using a nanofiber scaffold for tendon repair, Acta Biomaterialia, 9 (2013) 6905-6914.

[422] A. Chainani, K.J. Hippensteel, A. Kishan, N.W. Garrigues, D.S. Ruch, F. Guilak, D. Little, Multilayered electrospun scaffolds for tendon tissue engineering, Tissue Engineering Part A, 19 (2013) 2594-2604.

[423] S. Liu, J.W. Zhao, H.J. Ruan, T.T. Tang, G.W. Liu, D.G. Yu, W.G. Cui, C.Y. Fan, Biomimetic sheath membrane via electrospinning for antiadhesion of repaired tendon, Biomacromolecules, 13 (2012) 3611-3619.

[424] J. Zhu, J. Li, B. Wang, W.J. Zhang, G. Zhou, Y. Cao, W. Liu, The regulation of phenotype of cultured tenocytes by microgrooved surface structure, Biomaterials, 31 (2010) 6952-6958.

[425] W.Y. Tong, W. Shen, C.W.F. Yeung, Y. Zhao, S.H. Cheng, P.K. Chu, D. Chan, G.C.F. Chan, K.M.C. Cheung, K.W.K. Yeung, Y.W. Lam, Functional replication of the tendon tissue

microenvironment by a bioimprinted substrate and the support of tenocytic differentiation of mesenchymal stem cells, Biomaterials, 33 (2012) 7686-7698.

[426] P.O. Bagnaninchi, Y. Yang, A.J. El Haj, N. Maffulli, Tissue engineering for tendon repair, Br J Sports Med, 41 (2007) e10.

[427] L. Smith, P. Niziolek, K. Haberstroh, E. Nauman, T. Webster, Decreased fibroblast and increased osteoblast adhesion on nanostructured NaOH-etched PLGA scaffolds, International Journal of Nanomedicine, 2 (2007) 383-388.

[428] A. Inui, T. Kokubu, H. Fujioka, I. Nagura, R. Sakata, H. Nishimoto, M. Kotera, T. Nishino, M. Kurosaka, Application of layered poly (L-lactic acid) cell free scaffold in a rabbit rotator cuff defect model, Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology, 3 (2011) 29.

[429] D.S. Mastrokalos, H.H. Paessler, Allergic reaction to biodegradable interference poly-L-lactic acid screws after anterior cruciate ligament reconstruction with bone-patellar tendon-bone graft, Arthroscopy, 24 (2008) 732-733.

[430] L.P. McCarty, 3rd, D.D. Buss, M.W. Datta, M.Q. Freehill, M.R. Giveans, Complications observed following labral or rotator cuff repair with use of poly-L-lactic acid implants, The Journal of Bone and Joint Surgery-American Volume, 95 (2013) 507-511.

[431] L. Jozsa, A. Reffy, S. Demel, J.B. Balint, Foreign bodies in tendons, The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand, 14 (1989) 84-85.

[432] C. Agrawal, J. McKinney, D. Lanctot, K. Athanasiou, Effects of fluid flow on the *in vitro* degradation kinetics of biodegradable scaffolds for tissue engineering, Biomaterials, 21 (2000) 2443-2452.

[433] G. Chen, T. Ushida, T. Tateishi, Development of biodegradable porous scaffolds for tissue engineering, Materials Science and Engineering: C, 17 (2001) 63-69.

[434] D.S. Mastrokalos, H.H. Paessler, Allergic Reaction to Biodegradable Interference Poly-L-Lactic Acid Screws After Anterior Cruciate Ligament Reconstruction With Bone-Patellar Tendon-Bone Graft, Arthroscopy: The Journal of Arthroscopic & Related Surgery, 24 (2008) 732-733.

[435] A. Kikuchi, T. Okano, Nanostructured designs of biomedical materials: Applications of cell sheet engineering to functional regenerative tissues and organs, Journal of Controlled Release, 101 (2005) 69-84.

[436] Y. Miyahara, N. Nagaya, M. Kataoka, B. Yanagawa, K. Tanaka, H. Hao, K. Ishino, H. Ishida, T. Shimizu, K. Kangawa, S. Sano, T. Okano, S. Kitamura, H. Mori, Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction, Nature Medicine, 12 (2006) 459-465.

[437] M. Peck, N. Dusserre, T.N. McAllister, N. L'Heureux, Tissue engineering by self-assembly, Materials Today, 14 (2011) 218-224. [438] Y. Haraguchi, T. Shimizu, T. Sasagawa, H. Sekine, K. Sakaguchi, T. Kikuchi, W. Sekine, S. Sekiya, M. Yamato, M. Umezu, T. Okano, Fabrication of functional three-dimensional tissues by stacking cell sheets in vitro, Nature Protocols, 7 (2012) 850-858.

[439] K. Hemmrich, J. Salber, M. Meersch, U. Wiesemann, T. Gries, N. Pallua, D. Klee, Threedimensional nonwoven scaffolds from a novel biodegradable poly(ester amide) for tissue engineering applications, Journal of Materials Science: Materials in Medicine, 19 (2008) 257-267.

[440] S. Calve, R.G. Dennis, P.E. Kosnik, K. Baar, K. Grosh, E.M. Arruda, Engineering of functional tendon, Tissue Engineering, 10 (2004) 755-761.

[441] M. Ni, Y.F. Rui, Q. Tan, Y. Liu, L.L. Xu, K.M. Chan, Y. Wang, G. Li, Engineered scaffold-free tendon tissue produced by tendon-derived stem cells, Biomaterials, 34 (2013) 2024-2037.

[442] D. Cigognini, A. Lomas, P. Kumar, A. Satyam, A. English, A. Azeem, A. Pandit, D. Zeugolis, Engineering in vitro microenvironments for cell based therapies and drug discovery, Drug Discovery Today, 18 (2013) 1099-1108.

[443] G. Mitani, M. Sato, M. Yamato, M. Kokubo, T. Takagaki, G. Ebihara, T. Okano, J. Mochida, Potential utility of cell sheets derived from the anterior cruciate ligament and synovium fabricated in temperature-responsive culture dishes, Journal of Biomedical Materials Research Part A, 102 (2013) 2927-2933.

[444] Y. Inagaki, K. Uematsu, M. Akahane, Y. Morita, M. Ogawa, T. Ueha, T. Shimizu, T. Kura, K. Kawate, Y. Tanaka, Osteogenic matrix cell sheet transplantation enhances early tendon graft to bone tunnel healing in rabbits, Biomed Research International, 2013 (2013) 842192.

[445] S.B. Zimmerman, B. Harrison, Macromolecular crowding increases binding of DNA polymerase to DNA: An adaptive effect, Proceedings of the National Academy of Sciences of the United States of America, 84 (1987) 1871-1875.

[446] A.P. Minton, G.C. Colclasure, J.C. Parker, Model for the role of macromolecular crowding in regulation of cellular volume, Proceedings of the National Academy of Sciences of the United States of America, 90 (1993) 1137-1137.

[447] R.J. Ellis, A.P. Minton, Cell biology: Join the crowd, Nature, 425 (2003) 27-28.

[448] C. Chen, F. Loe, A. Blocki, Y. Peng, M. Raghunath, Applying macromolecular crowding to enhance extracellular matrix deposition and its remodeling in vitro for tissue engineering and cell-based therapies, Advanced Drug Delivery Reviews, 63 (2011) 277-290.

[449] A. Satyam, P. Kumar, X. Fan, A. Gorelov, Y. Rochev, L. Joshi, H. Peinado, D. Lyden, B. Thomas, B. Rodriguez, M. Raghunath, A. Pandit, D. Zeugolis, Macromolecular crowding meets tissue engineering by self-assembly: A paradigm shift in regenerative medicine, Advanced Materials, 26 (2014) 3024-3034.

[450] A.G. Smith, K. Kosygan, H. Williams, R.J. Newman, Common extensor tendon rupture following corticosteroid injection for lateral tendinosis of the elbow, Br J Sports Med, 33 (1999) 423-425.

[451] J.W. Strickland, The scientific basis for advances in flexor tendon surgery, Journal of Hand Therapy, 18 (2005) 94-110.

[452] D.K. Lee, Achilles tendon repair with acellular tissue graft augmentation in neglected ruptures, The Journal of Foot and Ankle Surgery, 46 (2007) 451-455.

[453] A. Soroceanu, F. Sidhwa, S. Aarabi, A. Kaufman, M. Glazebrook, Surgical versus nonsurgical treatment of acute Achilles tendon rupture a meta-analysis of randomized trials, Journal of Bone and Joint Surgery-American Volume, 94A (2012) 2136-2143.

[454] P. Reilly, I. Macleod, R. Macfarlane, J. Windley, R.J.H. Emery, Dead men anti radiologists don't lie: A review of cadaveric and radiological studies of rotator cuff tear prevalence, Annals of the Royal College of Surgeons of England, 88 (2006) 116-121.

[455] J.L. Bond, R.M. Dopirak, J. Higgins, J. Burns, S.J. Snyder, Arthroscopic replacement of massive, irreparable rotator cuff tears using a GraftJacket allograft: Technique and preliminary results, Arthroscopy, 24 (2008) 403-409.

[456] U. Longo, A. Berton, N. Papapietro, N. Maffulli, V. Denaro, Epidemiology, genetics and biological factors of rotator cuff tears, Medicine and Sport Science, 57 (2012) 1-9.

[457] E.T. Ricchetti, A. Aurora, J.P. Iannotti, K.A. Derwin, Scaffold devices for rotator cuff repair, Journal of Shoulder and Elbow Surgery, 21 (2012) 251-265.

[458] F. Contreras, H.C. Brown, R.G. Marx, Predictors of success of corticosteroid injection for the management of rotator cuff disease, HSS journal: The Musculoskeletal Journal of Hospital for Special Surgery, 9 (2013) 2-5.

[459] D. Saragaglia, A. Pison, B. Rubens-Duval, Acute and old ruptures of the extensor apparatus of the knee in adults (excluding knee replacement), Orthopaedics & Traumatology, Surgery & Research, 99 (2013) 67-76.

[460] G. Myklebust, R. Bahr, Return to play guidelines after anterior cruciate ligament surgery, Br J Sports Med, 39 (2005) 127-131.

[461] D.D. Frisbie, R.K.W. Smith, Clinical update on the use of mesenchymal stem cells in equine orthopaedics, Equine Veterinary Journal, 42 (2010) 86-89.

[462] S. Renzi, S. Ricco, S. Dotti, L. Sesso, S. Grolli, M. Cornali, S. Carlin, M. Patruno, S. Cinotti, M. Ferrari, Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: A clinical report, Research in Veterinary Science, 95 (2013) 272-277.

[463] S. Dyson, Proximal suspensory desmitis: clinical, ultrasonographic and radiographic features, Equine Veterinary Journal, 23 (1991) 25-31. [464] S. Dyson, Proximal suspensory desmitis in the hindlimb: 42 cases, Br Vet J, 150 (1994) 279-291.

[465] O.M. Crowe, S.J. Dyson, I.M. Wright, M.C. Schramme, R.K. Smith, Treatment of chronic or recurrent proximal suspensory desmitis using radial pressure wave therapy in the horse, Equine Veterinary Journal, 36 (2004) 313-316.

[466] G. Bosch, M. de Mos, R. van Binsbergen, H.T. van Schie, C.H. van de Lest, P.R. van Weeren, The effect of focused extracorporeal shock wave therapy on collagen matrix and gene expression in normal tendons and ligaments, Equine Veterinary Journal, 41 (2009) 335-341.

[467] P. Torricelli, M. Fini, G. Filardo, M. Tschon, M. Pischedda, A. Pacorini, E. Kon, R. Giardino, Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses, Int Orthop, 35 (2011) 1569-1576.

[468] M. Waselau, W.W. Sutter, R.L. Genovese, A.L. Bertone, Intralesional injection of plateletrich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses, J Am Vet Med Assoc, 232 (2008) 1515-1520.

[469] A.M. Urrea-Chávez, Regenerative medicine with platelet rich plasma: A therapy for tendonitis in equines, vet. zootec, 6 (2012) 79-86.

[470] M. Wagenhaeuser, M. Pietschmann, B. Sievers, D. Docheva, M. Schieker, V. Jansson, P. Mueller, Collagen type I and decorin expression in tenocytes depend on the cell isolation method, BMC Musculoskeletal Disorders, 13 (2012) 140.

[471] Y.F. Rui, P.P. Lui, G. Li, S.C. Fu, Y.W. Lee, K.M. Chan, Isolation and characterization of multipotent rat tendon-derived stem cells, Tissue Engineering Part A, 16 (2010) 1549-1558.

[472] J.B. Kouri, C. Arguello, J. Luna, R. Mena, Use of microscopical techniques in the study of human chondrocytes from osteoarthritic cartilage: an overview, Microscopy Research and Technique, 40 (1998) 22-36.

[473] M. Miettinen, A.E. Lindenmayer, A. Chaubal, Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens -- Evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor, Modern Pathology, 7 (1994) 82-90.

[474] A.J. Banes, K. Donlon, G.W. Link, Y. Gillespie, A.G. Bevin, H.D. Peterson, D. Bynum, S. Watts, L. Dahners, Cell populations of tendon: A simplified method for isolation of synovial cells and internal fibroblasts: Confirmation of origin and biologic properties, Journal of Orthopaedic Research, 6 (1988) 83-94.

[475] T. Nagase, T. Muneta, Y.J. Ju, K. Hara, T. Morito, H. Koga, A. Nimura, T. Mochizuki, I. Sekiya, Analysis of the chondrogenic potential of human synovial stem cells according to harvest

site and culture parameters in knees with medial compartment osteoarthritis, Arthritis and Rheumatism, 58 (2008) 1389-1398.

[476] G.K. Owens, M.S. Kumar, B.R. Wamhoff, Molecular regulation of vascular smooth muscle cell differentiation in development and disease, Physiological Reviews, 84 (2004) 767-801.

[477] M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop, E. Horwitz, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8 (2006) 315-317.

[478] B. Dowling, A. Dart, Mechanical and functional properties of the equine superficial digital flexor tendon, The Veterinary Journal, 170 (2005) 184-192.

[479] C.T. Thorpe, C.P. Udeze, H.L. Birch, P.D. Clegg, H.R. Screen, Specialization of tendon mechanical properties results from interfascicular differences, Journal of The Royal Society Interface, 9 (2012) 3108-3117.

[480] C. Thorpe, R. Stark, A. Goodship, H. Birch, Mechanical properties of the equine superficial digital flexor tendon relate to specific collagen cross-link levels, Equine Veterinary Journal, 42 (2010) 538-543.

[481] T.A. Wren, S.A. Yerby, G.S. Beaupré, D.R. Carter, Mechanical properties of the human Achilles tendon, Clinical Biomechanics, 16 (2001) 245-251.

[482] M. Kongsgaard, C.H. Nielsen, S. Hegnsvad, P. Aagaard, S.P. Magnusson, Mechanical properties of the human Achilles tendon, in vivo, Clinical Biomechanics, 26 (2011) 772-777.

[483] G. Lewis, K.M. Shaw, Tensile properties of human tendo achillis: Effect of donor age and strain rate, The Journal of Foot and Ankle Surgery, 36 (1997) 435-445.

[484] J.E. Carpenter, J.D. Wening, A.G. Mell, J.E. Langenderfer, J.E. Kuhn, R.E. Hughes, Changes in the long head of the biceps tendon in rotator cuff tear shoulders, Clinical Biomechanics, 20 (2005) 162-165.

[485] P. Reilly, A.A. Amis, A.L. Wallace, R.J. Emery, Mechanical factors in the initiation and propagation of tears of the rotator cuff. Quantification of strains of the supraspinatus tendon in vitro, The Journal of Bone and Joint Surgery-British Volume, 85 (2003) 594-599.

[486] A. Halder, M.E. Zobitz, F. Schultz, K.N. An, Mechanical properties of the posterior rotator cuff, Clinical Biomechanics, 15 (2000) 456-462.

[487] C. Couppé, C. Suetta, M. Kongsgaard, L. Justesen, L. Hvid, P. Aagaard, M. Kjaer, S.P. Magnusson, The effects of immobilization on the mechanical properties of the patellar tendon in younger and older men, Clinical Biomechanics, 27 (2012) 949-954.

[488] G.A. Johnson, D.M. Tramaglini, R.E. Levine, K. Ohno, N.Y. Choi, S. L-Y Woo, Tensile and viscoelastic properties of human patellar tendon, Journal of Orthopaedic Research, 12 (1994) 796-803.

[489] I. Mabe, S. Hunter, Quadriceps tendon allografts as an alternative to Achilles tendon allografts: A biomechanical comparison, Cell and Tissue banking, 15 (2014) 523-529.

[490] J. Hashemi, N. Chandrashekar, J. Slauterbeck, The mechanical properties of the human patellar tendon are correlated to its mass density and are independent of sex, Clinical Biomechanics, 20 (2005) 645-652.

[491] A.W. Pearsall IV, J.M. Hollis, G.V. Russell Jr, Z. Scheer, A biomechanical comparison of three lower extremity tendons for ligamentous reconstruction about the knee, Arthroscopy, 19 (2003) 1091-1096.

[492] T.L. Haut Donahue, S.M. Howell, M.L. Hull, C. Gregersen, A biomechanical evaluation of anterior and posterior tibialis tendons as suitable single-loop anterior cruciate ligament grafts, Arthroscopy, 18 (2002) 589-597.

[493] L.L. Greaves, A.T. Hecker, C.H. Brown, The effect of donor age and low-dose gamma irradiation on the initial biomechanical properties of human tibialis tendon allografts, Am J Sports Med, 36 (2008) 1358-1366.

[494] S.A. Rodeo, Biologic augmentation of rotator cuff tendon repair, Journal of Shoulder and Elbow Surgery, 16 (2007) S191-S197.

[495] A. Oryan, A. Moshiri, A. Parizi Meimandi, I.A. Silver, A long-term in vivo investigation on the effects of xenogenous based, electrospun, collagen implants on the healing of experimentallyinduced large tendon defects, Journal of Musculoskeletal and Neuronal Interactions, 13 (2013) 353-367.

[496] J.F. Cavallaro, P.D. Kemp, K.H. Kraus, Collagen fabrics as biomaterials, Biotechnology and Bioengineering, 43 (1994) 781-791.

[497] T.J. Koob, D.J. Hernandez, Material properties of polymerized NDGA-collagen composite fibers: Development of biologically based tendon constructs, Biomaterials, 23 (2002) 203-212.

[498] D. Goupil, Sutures, in: Ratner, B., Hoffman, A., Schoen, F., Lemons, J. (Eds.) Biomaterials Science. An introduction to Materials In Medicine, Academic Press, London, 1996, pp. 356-360.

[499] L. Bosworth, N. Alam, J. Wong, S. Downes, Investigation of 2D and 3D electrospun scaffolds intended for tendon repair, Journal of Materials Science: Materials in Medicine, 24 (2013) 1605-1614.

[500] K.L. Moffat, A.S. Kwei, J.P. Spalazzi, S.B. Doty, W.N. Levine, H.H. Lu, Novel nanofiberbased scaffold for rotator cuff repair and augmentation, Tissue Engineering Part A, 15 (2009) 115-126. [501] A. English, A. Azeem, D.A. Gaspar, K. Keane, P. Kumar, M. Keeney, N. Rooney, A. Pandit, D.I. Zeugolis, Preferential cell response to anisotropic electro-spun fibrous scaffolds under tension-free conditions, Journal of Materials Science: Materials in Medicine, 23 (2012) 137-148.

[502] Z. Yin, X. Chen, J.L. Chen, W.L. Shen, T.M.H. Nguyen, L. Gao, H.W. Ouyang, The regulation of tendon stem cell differentiation by the alignment of nanofibers, Biomaterials, 31 (2010) 2163-2175.